<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38603800</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Use of Darvadstrocel (Allogenic Stem Cell Therapy) for Crohn's Fistulas in Real Clinical Practice: The National Project to Implement Mesenchymal Stem Cell for the Treatment of Perianal Crohn's Fistula (the PRIME Study).</ArticleTitle><Pagination><StartPage>960</StartPage><EndPage>967</EndPage><MedlinePgn>960-967</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003216</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Perianal fistulas may affect 15% to 50% of patients with Crohn's disease. Treatment is complex, requiring a multidisciplinary approach. Darvadstrocel (allogenic mesenchymal cells obtained from lipoaspirates) was approved in 2018 by the European and Spanish Agencies of Medicines and Medical Products as a treatment for fistulas in Crohn's disease. Recent guidelines from the European Crohn's and Colitis Organisation and Spanish Working Group on Crohn's Disease and Ulcerative Colitis state that darvadstrocel is effective with a favorable safety profile and a strong level of evidence (n&#x2009;=&#x2009;2).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Presenting real-world effectiveness data for darvadstrocel in a Spanish population.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Observational retrospective cohort study with prospective data gathering.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">The study was conducted at 14 institutions in Spain.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">From November 2019 to April 2022, all patients (n = 73) treated with darvadstrocel in these institutions were included, fulfilling the following criteria: 1) complex fistula/s in a patient with Crohn's disease; 2) failure of conventional and antitumor necrosis factor treatment; and 3) the absence of collections of &gt;2&#x2009;cm confirmed by pelvic MRI at the time of surgery.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Darvadstrocel treatment.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Clinical response (closure of 50% or more of external openings), complete clinical closure (100% of external openings), and radiological closure (no fluid collection &gt;2&#x2009;cm, edema, or inflammation) evaluated 6 months after treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Clinical response was observed in 63 patients (86.3%), complete clinical closure in 50 patients (68.5%), and radiological closure in 45 patients (69.2%). Combined clinical and radiological response was observed in 41 patients (63.1%). Not all clinically healed patients had radiological closure, and vice versa. No serious adverse events were reported.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Retrospective nature of the study.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Study results were consistent with those reported in previous clinical trials, real-world efficacy findings from the INSPIRE study (assessing darvadstrocel effectiveness in Europe, Israel, Switzerland, United Kingdom, and Japan), and previously published literature. Darvadstrocel was effective and demonstrated a favorable safety profile when used in normal clinical practice for the treatment of fistulas in Crohn's disease. See Video Abstract .</AbstractText><AbstractText Label="USO DE DARVADSTROCEL TERAPIA CON CLULAS MADRE ALOGNICAS PARA FSTULA EN ENFERMEDAD DE CROHN EN LA PRCTICA CLNICA REAL EL PROYECTO NACIONAL PARA IMPLEMENTAR DE CLULAS MADRE MESENQUIMALES PARA EL TRATAMIENTO DE LA FSTULA DE CROHN PERIANAL EL ESTUDIO PRIME" NlmCategory="UNASSIGNED">ANTECEDENTES:Las f&#xed;stulas perianales pueden afectar entre el 15 y el 50% de los pacientes con enfermedad de Crohn. El tratamiento es complejo y requiere un enfoque multidisciplinario. El darvadstrocel (c&#xe9;lulas mesenquimales alog&#xe9;nicas obtenidas a partir de lipoaspirados) fue aprobado en 2018 por las Agencias Europea y Espa&#xf1;ola de Medicamentos y Productos Sanitarios como tratamiento de las f&#xed;stulas en la EC. Las recientes directrices de la Organizaci&#xf3;n Europea de Crohn y Colitis y del Grupo de Trabajo Espa&#xf1;ol sobre la Enfermedad de Crohn y Colitis Ulcerosa afirman que darvadstrocel es eficaz con un perfil de seguridad favorable y un s&#xf3;lido nivel de evidencia (2).OBJETIVO:Presentar datos de eficacia real de darvadstrocel en poblaci&#xf3;n espa&#xf1;ola.DISE&#xd1;O:Estudio de cohorte retrospectivo observacional con recopilaci&#xf3;n prospectiva de datos.ESCENARIO:14 instituciones.PACIENTES:Desde noviembre de 2019 hasta abril de 2022, se incluyeron todos los pacientes (73) tratados con darvadstrocel en estas instituciones, que cumplieron los siguientes criterios: 1) f&#xed;stula/s compleja/s en un paciente con enfermedad de Crohn; 2) fracaso del tratamiento convencional y anti factor de necrosis tumoral; 3) ausencia de colecciones &gt; 2 cm confirmada por resonancia magn&#xe9;tica p&#xe9;lvica en el momento de la cirug&#xed;a.INTERVENCIONES:Tratamiento con Darvadstrocel.PRINCIPALES MEDIDAS DE RESULTADO:Respuesta cl&#xed;nica (cierre de &#x2265;50% de las aberturas externas), cierre cl&#xed;nico completo (100% de las aberturas externas) y cierre radiol&#xf3;gico (sin acumulaci&#xf3;n de l&#xed;quido &gt;2 cm, sin edema ni inflamaci&#xf3;n) evaluados 6 meses despu&#xe9;s del tratamiento.RESULTADOS:Se observ&#xf3; respuesta cl&#xed;nica en 63 pacientes (86.3%), cierre cl&#xed;nico completo en 50 pacientes (68.5%) y cierre radiol&#xf3;gico en 45 pacientes (69.2%). Se observ&#xf3; respuesta cl&#xed;nica y radiol&#xf3;gica combinada en 41 pacientes (63.1%). No todos los pacientes cl&#xed;nicamente curados tuvieron cierre radiol&#xf3;gico y viceversa. No hubo eventos adversos graves reportados.LIMITACIONES:Estudio retrospectivoCONCLUSIONES:Los resultados del estudio fueron consistentes con los informados en ensayos cl&#xed;nicos anteriores, los hallazgos de eficacia en el mundo real del estudio INSPIRE (que eval&#xfa;a la efectividad de darvadstrocel en Europa, Israel, Suiza, el Reino Unido y Jap&#xf3;n) y la literatura publicada anteriormente. Darvadstrocel fue eficaz y demostr&#xf3; un perfil de seguridad favorable cuando se utiliza en la pr&#xe1;ctica cl&#xed;nica habitual para el tratamiento de f&#xed;stulas en la enfermedad de Crohn. (Traducci&#xf3;n-Dr. Jorge Silva Velazco ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herreros</LastName><ForeName>Maria Dolores</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0002-1136-4518</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University Hospital Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New Therapy Laboratory, Instituto de Investigaci&#xf3;n Sanitaria Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Jose-Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Zaragoza, Zaragoza, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spanish Multimodal Rehabilitation Group (GERM), Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otero-Pi&#xf1;eiro</LastName><ForeName>Ana M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital Clinic, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;-Gallostra</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital Vall Hebron, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badiola</LastName><ForeName>Izaskun</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Surgery University Hospital Galdakao-Usansolo, Vizcaya, Pais Vasco, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enr&#xed;quez-Navascues</LastName><ForeName>Jose M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital Donostia, Biodonostia, San Sebastian, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Millan</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital la Fe, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barreiro</LastName><ForeName>Erica M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital of Pontevedra, Galicia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De La Portilla</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Surgery University Hospital Virgen del Rocio, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su&#xe1;rez Alecha</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital of Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Olmo</LastName><ForeName>Damian</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New Therapy Laboratory, Instituto de Investigaci&#xf3;n Sanitaria Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surgery Department, Universidad Autonoma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>National Project to Implement Mesenchymal Stem Cell for the Treatment of Perianal Crohn&#x2019;s Fistula (the PRIME Study) Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05742100</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="Y">Crohn Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012003" MajorTopicYN="Y">Rectal Fistula</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="Y">Mesenchymal Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Herreros</LastName><ForeName>Maria Dolores</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garc&#xed;a-Olmo</LastName><ForeName>Damian</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guadalajara</LastName><ForeName>Hector</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garcia-Arranz</LastName><ForeName>Mariano</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Jose-Manuel</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Badiola</LastName><ForeName>Izaskun</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fern&#xe1;ndez Miguel</LastName><ForeName>Tamara</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodr&#xed;guez Lago</LastName><ForeName>Iago</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Portugal Porras</LastName><ForeName>Vicente</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Golda</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galvez</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruiz Cerulla</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kreisler</LastName><ForeName>Esther</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Otero</LastName><ForeName>Ana M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tavares</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pena</LastName><ForeName>Romina</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bravo</LastName><ForeName>Raquel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Enr&#xed;quez-Navascues</LastName><ForeName>Jose M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Placer</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borda</LastName><ForeName>Nerea</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elorza</LastName><ForeName>Garazi</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Millan</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez Chicote</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cholewa</LastName><ForeName>Hanna</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nieto</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marti</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Espin</LastName><ForeName>Eloi</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borruel</LastName><ForeName>Natalia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Armario Quiteria Hern&#xe1;ndez</LastName><ForeName>Davis</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abrisqueta</LastName><ForeName>Jes&#xfa;s</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ib&#xe1;&#xf1;ez</LastName><ForeName>Noelia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montoya</LastName><ForeName>Mariano</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>De La Portilla</LastName><ForeName>Fernando</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>V&#xe1;zquez Monchul</LastName><ForeName>Jorge M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>de la Portilla Le&#xf3;n</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gomez-Rosado</LastName><ForeName>Juan-Carlos</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torres-Arcos</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perez-Sanchez</LastName><ForeName>Asuncion</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arg&#xfc;elles-Arias</LastName><ForeName>Federico</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barreiro</LastName><ForeName>Erica</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez de Los Reyes</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanchez-Guillen</LastName><ForeName>Luis</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alcaide-Quir&#xf3;s</LastName><ForeName>M Jos&#xe9;</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arroyo</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>L&#xf3;pez-Rodr&#xed;guez-Arias</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suarez Alecha</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oronoz</LastName><ForeName>Bego&#xf1;a</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rubio</LastName><ForeName>Saioa</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vicu&#xf1;a</LastName><ForeName>Miren</ForeName><Initials>M</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>13</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>11</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>11</Day><Hour>17</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38603800</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003216</ArticleId><ArticleId IdType="pii">00003453-202407000-00014</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. Br J Surg. 1976;63:1&#x2013;12.</Citation></Reference><Reference><Citation>Vigano C, Losco A, Caprioli F, Basilisco G. Incidence and clinical outcomes of intersphincteric abscesses diagnosed by anal ultrasonography in patients with Crohn&#x2019;s disease. Inflamm Bowel Dis. 2011;17:2102&#x2013;2108.</Citation></Reference><Reference><Citation>Limura E, Giordano P. Modern management of anal fistula. World J Gastroenterol. 2015;21:12&#x2013;20.</Citation></Reference><Reference><Citation>Panes J, Rimola J. Perianal fistulizing Crohn&#x2019;s disease: pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14:652&#x2013;664.</Citation></Reference><Reference><Citation>Sainio P. Fistula-in-ano in a defined population. Incidence and epidemiological aspects. Ann Chir Gynaecol. 1984;73:219&#x2013;224.</Citation></Reference><Reference><Citation>Garcia-Olmo D, Van Assche G, Tagarro I, et al. Prevalence of anal fistulas in Europe: systematic literature reviews and population-based database analysis. Adv Ther. 2019;36:3503&#x2013;3518.</Citation></Reference><Reference><Citation>Wasmann KA, de Groof EJ, Stellingwerf ME, et al. Treatment of perianal fistulas in Crohn&#x2019;s disease, seton versus anti-TNF versus surgical closure following anti-TNF [PISA]: a randomised controlled trial. J Crohns Colitis. 2020;14:1049&#x2013;1056.</Citation></Reference><Reference><Citation>Hellers G, Bergstrand O, Ewerth S, Holmstrom B. Occurrence and outcome after primary treatment of anal fistulae in Crohn&#x2019;s disease. Gut. 1980;21:525&#x2013;527.</Citation></Reference><Reference><Citation>Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn&#x2019;s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875&#x2013;880.</Citation></Reference><Reference><Citation>Adamina M, Bonovas S, Raine T, et al. ECCO guidelines on therapeutics in Crohn&#x2019;s disease: surgical treatment. J Crohns Colitis. 2020;14:155&#x2013;168.</Citation></Reference><Reference><Citation>Panes J, Garcia-Olmo D, Van Assche G, et al.; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn&#x2019;s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388:1281&#x2013;1290.</Citation></Reference><Reference><Citation>Schwandner O. Stem cell injection for complex anal fistula in Crohn&#x2019;s disease: a single-center experience. World J Gastroenterol. 2021;27:3643&#x2013;3653.</Citation></Reference><Reference><Citation>Cabalzar-Wondberg D, Turina M, Biedermann L, Rogler G, Schreiner P. Allogeneic expanded adipose-derived mesenchymal stem cell therapy for perianal fistulas in Crohn&#x2019;s disease: a case series. Colorectal Dis. 2021;23:1444&#x2013;1450.</Citation></Reference><Reference><Citation>Herreros MD, Garcia-Arranz M, Guadalajara H, De-La-Quintana P, Garcia-Olmo D; FATT Collaborative Group. Autologous expanded adipose-derived stem cells for the treatment of complex cryptoglandular perianal fistulas: a phase III randomized clinical trial (FATT 1: fistula Advanced Therapy Trial 1) and long-term evaluation. Dis Colon Rectum. 2012;55:762&#x2013;772.</Citation></Reference><Reference><Citation>Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009;52:79&#x2013;86.</Citation></Reference><Reference><Citation>Garcia-Olmo D, Herreros D, De-La-Quintana P, et al. Adipose-derived stem cells in Crohn&#x2019;s rectovaginal fistula. Case Rep Med. 2010;2010:961758.</Citation></Reference><Reference><Citation>Garcia-Arranz M, Herreros MD, Gonzalez-Gomez C, et al. Treatment of Crohn&#x2019;s-related rectovaginal fistula with allogeneic expanded-adipose derived stem cells: a phase I-IIa clinical trial. Stem Cells Transl Med. 2016;5:1441&#x2013;1446.</Citation></Reference><Reference><Citation>Garcia-Olmo D, Garcia-Arranz M, Herreros D. Expanded adipose-derived stem cells for the treatment of complex perianal fistula including Crohn&#x2019;s disease. Expert Opin Biol Ther. 2008;8:1417&#x2013;1423.</Citation></Reference><Reference><Citation>Georgiev-Hristov T, Guadalajara H, Herreros MD, et al. A step-by-step surgical protocol for the treatment of perianal fistula with adipose-derived mesenchymal stem cells. J Gastrointest Surg. 2018;22:2003&#x2013;2012.</Citation></Reference><Reference><Citation>Kamal N, Motwani K, Wellington J, Wong U, Cross RK. Fecal incontinence in inflammatory bowel disease. Crohns Colitis 360. 2021;3:otab013.</Citation></Reference><Reference><Citation>Park SH, Aniwan S, Scott Harmsen W, et al. Update on the natural course of fistulizing perianal Crohn&#x2019;s disease in a population-based cohort. Inflamm Bowel Dis. 2019;25:1054&#x2013;1060.</Citation></Reference><Reference><Citation>Garcia-Olmo D, Garcia-Arranz M, Garcia LG, et al. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn&#x2019;s disease: a new cell-based therapy. Int J Colorectal Dis. 2003;18:451&#x2013;454.</Citation></Reference><Reference><Citation>Garcia-Olmo D, Gilaberte I, Binek M, et al. Follow-up study to evaluate the long-term safety and efficacy of darvadstrocel (mesenchymal stem cell treatment) in patients with perianal fistulizing Crohn&#x2019;s disease: ADMIRE-CD phase 3 randomized controlled trial. Dis Colon Rectum. 2022;65:713&#x2013;720.</Citation></Reference><Reference><Citation>Zamora O, Baumgart DC, Faubion W, et al. P603 INSPIRE: 6-month interim analysis from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn&#x2019;s disease and complex perianal fistulas. J Crohns Colitis. 2022;16:i536&#x2013;i537.</Citation></Reference><Reference><Citation>Borruel N, Mart&#xed; M, Armario D, et al. P297 Treatment of patients with complex perianal Crohn&#x2019;s disease with darvadstrocel: a single-institution real life experience. J Crohns Colitis. 2022;16:i326&#x2013;i327.</Citation></Reference><Reference><Citation>Elorza A, Arzallus T, Izagirre A, et al. P390 Efficacy and safety of mesenchymal stem cell therapy with darvadstrocel for complex perianal fistulizing Crohn&#x2019;s disease: multicentric experience in the Basque Country and Navarre. J Crohns Colitis. 2022;16:i388&#x2013;i388.</Citation></Reference><Reference><Citation>Dawoud C, Widmann KM, Czipin S, et al. Efficacy of cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn&#x2019;s disease&#x2014;a prospective nationwide multicenter cohort study. Wien Klin Wochenschr. 2023.</Citation></Reference><Reference><Citation>Fathallah N, Siproudhis L, Akaffou M, et al. Allogenic stem cells for Crohn&#x2019;s anal fistulas: treating early improves the deep remission rate. Colorectal Dis. 2023;25:2170&#x2013;2176.</Citation></Reference><Reference><Citation>Fathallah N, Akaffou M, Haouari MA, et al. Deep remission improves the quality of life of patients with Crohn&#x2019;s disease and anoperineal fistula treated with darvadstrocel: results of a French pilot study. Tech Coloproctol. 2023;27:1201&#x2013;1210.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38547350</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1876-3405</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>16 Suppl 1</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>28</Day></PubDate></JournalIssue><Title>International health</Title><ISOAbbreviation>Int Health</ISOAbbreviation></Journal><ArticleTitle>A pilot study to address the mental health of persons living with lymphatic filariasis in L&#xe9;og&#xe2;ne, Haiti: Implementing a chronic disease self-management program using a stepped-wedge cluster design.</ArticleTitle><Pagination><StartPage>i68</StartPage><EndPage>i77</EndPage><MedlinePgn>i68-i77</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/inthealth/ihae006</ELocationID><Abstract><AbstractText Label="BACKGROUND">Neglected tropical diseases (NTDs) inflict significant comorbid disability on the most vulnerable communities; yet interventions targeting the mental health of affected communities are lacking. A pilot study to assess the effectiveness of a chronic disease self-management program (CDSMP) was introduced to lymphatic filariasis peer support groups in L&#xe9;og&#xe2;ne, Haiti.</AbstractText><AbstractText Label="METHODS">Using a closed-cohort stepped-wedge cluster trial design, Hope Clubs were assigned into Arm 1 (n=118 members) and Arm 2 (n=92). Household surveys, measuring self-rated health, depression, disease self-efficacy, perceived social support, and quality of life, were conducted at baseline (before CDSMP); midpoint (after Arm 1/before Arm 2 completed CDSMP); and endpoint (after CDSMP). Non-Hope Club member patients (n=74) were evaluated at baseline for comparison.</AbstractText><AbstractText Label="RESULTS">Fifty percent of Hope Club members (Arm 1: 48.3%, Arm 2: 52.2%) screened positive for depression at baseline, compared with 36.5% of non-Hope Club members. No statistically significant differences were found in outcome measures between intervention observation periods. At endpoint, depressive illness reduced to 28.7% (Arm 1) and 27.6% (Arm 2).</AbstractText><AbstractText Label="CONCLUSIONS">The intervention was feasible to integrate into Hope Clubs, showed overall positive effects and reduced depressive symptoms. More studies are needed to evaluate the efficacy of implementing CDSMP in the NTD context.</AbstractText><AbstractText Label="CONTEXTE">Les maladies tropicales n&#xe9;glig&#xe9;es (MTN) infligent d'importantes incapacit&#xe9;s comorbides aux communaut&#xe9;s les plus vuln&#xe9;rables; pourtant, les interventions ciblant la sant&#xe9; mentale des communaut&#xe9;s affect&#xe9;es font d&#xe9;faut. Une &#xe9;tude pilote visant &#xe0; &#xe9;valuer l'efficacit&#xe9; d'un programme d'autogestion des maladies chroniques (CDSMP) a &#xe9;t&#xe9; introduite dans des groupes de soutien par les pairs pour la filariose lymphatique &#xe0; L&#xe9;og&#xe2;ne, en Ha&#xef;ti.</AbstractText><AbstractText Label="M&#xc9;THODES">Dans le cadre d'un essai en grappe &#xe0; cohorte ferm&#xe9;e, les clubs Hope ont &#xe9;t&#xe9; r&#xe9;partis entre le bras 1 (n=118 membres) et le bras 2 (n=92). Des enqu&#xea;tes aupr&#xe8;s des m&#xe9;nages, mesurant l'auto-&#xe9;valuation de la sant&#xe9;, la d&#xe9;pression, l'auto-efficacit&#xe9; face &#xe0; la maladie, le soutien social per&#xe7;u et la qualit&#xe9; de vie, ont &#xe9;t&#xe9; men&#xe9;es au d&#xe9;part (avant le CDSMP), &#xe0; mi-parcours (apr&#xe8;s que le bras 1 / avant que le bras 2 ait termin&#xe9; le CDSMP) et &#xe0; la fin (apr&#xe8;s le CDSMP). Les patients non membres du Hope Club (n=74) ont &#xe9;t&#xe9; &#xe9;valu&#xe9;s au d&#xe9;but de l'&#xe9;tude &#xe0; des fins de comparaison.</AbstractText><AbstractText Label="R&#xc9;SULTATS">Cinquante pourcent des membres du Hope Club (bras 1 : 48,3%, bras 2 : 52,2%) ont &#xe9;t&#xe9; d&#xe9;pist&#xe9;s positifs pour la d&#xe9;pression au d&#xe9;but de l'&#xe9;tude, contre 36,5% des non-membres du Hope Club. Aucune diff&#xe9;rence statistiquement significative n'a &#xe9;t&#xe9; constat&#xe9;e dans les mesures des r&#xe9;sultats entre les p&#xe9;riodes d'observation de l'intervention. &#xc0; la fin de l'&#xe9;tude, la maladie d&#xe9;pressive &#xe9;tait r&#xe9;duite &#xe0; 28,7% (bras 1) et 27,6% (bras 2).</AbstractText><AbstractText Label="CONCLUSIONS">L'intervention a pu &#xea;tre int&#xe9;gr&#xe9;e dans les clubs Hope, elle a montr&#xe9; des effets globalement positifs et a permis de r&#xe9;duire les sympt&#xf4;mes d&#xe9;pressifs. D'autres &#xe9;tudes sont n&#xe9;cessaires pour &#xe9;valuer l'efficacit&#xe9; de la mise en &#x153;uvre du CDSMP dans le contexte des MTD.</AbstractText><AbstractText Label="ANTECEDENTES">Las enfermedades tropicales desatendidas (ETDs) infligen una importante discapacidad com&#xf3;rbida a las comunidades m&#xe1;s vulnerables; sin embargo, faltan intervenciones dirigidas a la salud mental de las comunidades afectadas. Se introdujo un estudio piloto para evaluar la eficacia de un programa de autogesti&#xf3;n de enfermedades cr&#xf3;nicas (CDSMP, por sus siglas en ingl&#xe9;s) en grupos de apoyo entre pares de filariasis linf&#xe1;tica en L&#xe9;og&#xe2;ne, Hait&#xed;.</AbstractText><AbstractText Label="M&#xc9;TODOS">Utilizando un dise&#xf1;o de ensayo por conglomerados de cohortes cerradas escalonadas, los Clubes Esperanza fueron asignados al Grupo 1 (n=118 miembros) y al Grupo 2 (n=92). Se realizaron encuestas en los hogares para medir la autoevaluaci&#xf3;n de la salud, la depresi&#xf3;n, la autoeficacia frente a la enfermedad, el apoyo social percibido y la calidad de vida en la l&#xed;nea de base (antes del CDSMP), en el punto medio (despu&#xe9;s de que el Grupo 1/antes de que el Grupo 2 completara el CDSMP) y en el punto final (despu&#xe9;s del CDSMP). Los pacientes que no pertenec&#xed;an al Club Esperanza (n=74) fueron evaluados al inicio del estudio a modo de comparaci&#xf3;n.</AbstractText><AbstractText Label="RESULTADOS">El 50% de los miembros del Club Esperanza (Grupo 1: 48,3%, Grupo 2: 52,2%) dieron positivo en depresi&#xf3;n al inicio del estudio, en comparaci&#xf3;n con el 36,5% de los no miembros del Club Esperanza. No se encontraron diferencias estad&#xed;sticamente significativas en las medidas de resultado entre los periodos de observaci&#xf3;n de la intervenci&#xf3;n. Al final, la enfermedad depresiva se redujo al 28,7% (Grupo 1) y al 27,6% (Grupo 2).</AbstractText><AbstractText Label="CONCLUSIONES">La intervenci&#xf3;n fue factible de integrar en los Clubes Esperanza, mostr&#xf3;efectos positivos generales y redujo los s&#xed;ntomas depresivos. Se necesitan m&#xe1;s estudios para evaluar la eficacia de la aplicaci&#xf3;n del CDSMP en el contexto de las ETD.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sadiq</LastName><ForeName>Shanze</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mental Health Program, The Carter Center, Atlanta, GA, 30307, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamre</LastName><ForeName>Karen E S</ForeName><Initials>KES</Initials><AffiliationInfo><Affiliation>Hispaniola Initiative, The Carter Center, Atlanta, GA, 30307, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Samhita</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mental Health Program, The Carter Center, Atlanta, GA, 30307, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bazur-Leidy</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mental Health Program, The Carter Center, Atlanta, GA, 30307, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xe9;sir</LastName><ForeName>Lucc&#xe8;ne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hispaniola Initiative, The Carter Center, Atlanta, GA, 30307, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xe9;sir</LastName><ForeName>M Martha</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Notre Dame Haiti Program, University of Notre Dame, Port-au-Prince, Haiti.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>Murielle C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>National Program to Eliminate Lymphatic Filariasis, Ministry of Public Health and Population, Port-au-Prince, Haiti.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beau de Rochars</LastName><ForeName>V Madsen</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Hispaniola Initiative, The Carter Center, Atlanta, GA, 30307, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Services Research, Management and Policy, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Telfort</LastName><ForeName>Marc-Aur&#xe8;le</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>National Program to Eliminate Lymphatic Filariasis, Ministry of Public Health and Population, Port-au-Prince, Haiti.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noland</LastName><ForeName>Gregory S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Hispaniola Initiative, The Carter Center, Atlanta, GA, 30307, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrd</LastName><ForeName>Eve</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Mental Health Program, The Carter Center, Atlanta, GA, 30307, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Bill and Melinda Gates Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Health</MedlineTA><NlmUniqueID>101517095</NlmUniqueID><ISSNLinking>1876-3405</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="Y">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006205" MajorTopicYN="N" Type="Geographic">Haiti</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008603" MajorTopicYN="N">Mental Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073278" MajorTopicYN="Y">Self-Management</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chronic disease self-management</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">lymphatic filariasis</Keyword><Keyword MajorTopicYN="N">mental health</Keyword><Keyword MajorTopicYN="N">neglected tropical diseases</Keyword></KeywordList><CoiStatement>SK is a Guest Editor of this supplement but had no role in the review of this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>28</Day><Hour>18</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>28</Day><Hour>14</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38547350</ArticleId><ArticleId IdType="pmc">PMC10977951</ArticleId><ArticleId IdType="doi">10.1093/inthealth/ihae006</ArticleId><ArticleId IdType="pii">7636814</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Centers for Disease Control and Prevention . Neglected Tropical Diseases. https://www.cdc.gov/globalhealth/ntd/index.html [accessed 23 September 2022].</Citation></Reference><Reference><Citation>Kuper &#xa0;H. &#xa0;Neglected tropical diseases and disability&#x2014;what is the link? &#xa0;Trans R Soc Trop. 2019;113(12):839&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6903791</ArticleId><ArticleId IdType="pubmed">30892653</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021&#x2013;2030 . Geneva: World Health Organization, 2020.</Citation></Reference><Reference><Citation>Person &#xa0;B, Bartholomew &#xa0;LK, Addiss &#xa0;D, et al. &#xa0;Disrupted social connectedness among Dominican women with chronic filarial lymphedema. Patient Educ Couns. 2007;68(3):279&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">17707609</ArticleId></ArticleIdList></Reference><Reference><Citation>Person &#xa0;B, Bartholomew &#xa0;LK, Gyapong &#xa0;M, et al. &#xa0;Health-related stigma among women with lymphatic filariasis from the Dominican Republic and Ghana. Soc Sci Med. 2009;68(1):30&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18992982</ArticleId></ArticleIdList></Reference><Reference><Citation>Obindo &#xa0;J, Abdulmalik &#xa0;J, Nwefoh &#xa0;E, et al. &#xa0;Prevalence of depression and associated clinical &#xa0;and socio-demographic factors in people living with lymphatic filariasis in Plateau State, Nigeria. PLOS Negl Trop Dis. 2017;11(6):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5453421</ArticleId><ArticleId IdType="pubmed">28570585</ArticleId></ArticleIdList></Reference><Reference><Citation>Molyneux &#xa0;DH, Dean &#xa0;L, Adekeye &#xa0;O, et al. &#xa0;The changing global landscape of health and disease: Addressing challenges and opportunities for sustaining progress towards control and elimination of neglected tropical diseases (NTDs). Parasitology. 2018;145(13):1647&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">29547362</ArticleId></ArticleIdList></Reference><Reference><Citation>Ton &#xa0;TGN, Mackenzie &#xa0;C, Molyneux &#xa0;DH. &#xa0;The burden of mental health in lymphatic filariasis. Infect Dis Pov. 2015;4:34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4520254</ArticleId><ArticleId IdType="pubmed">26229599</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Lymphatic filariasis: Managing morbidity and preventing disability: An aide-memoire for national programme managers. World Health Organization. 2013; (1):1&#x2013;67.</Citation></Reference><Reference><Citation>Oscar &#xa0;R, Lemoine &#xa0;JF, Direny &#xa0;AN, et al. &#xa0;Haiti national program for the elimination of lymphatic filariasis-a model of success in the face of adversity. PLoS Negl Trop Dis. 2014;8(7):915.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4102456</ArticleId><ArticleId IdType="pubmed">25032697</ArticleId></ArticleIdList></Reference><Reference><Citation>
The Carter Center . Eliminating malaria from Hispaniola: A binational effort. Summary 2021 Virtual Progra m Review Hispaniola Initiative. https://www.cartercenter.org/resources/pdfs/news/health_publications/hispaniola/2021-carter-center-hispaniola-initiative-proceedings-summary.pdf [accessed 1 May 2023].</Citation></Reference><Reference><Citation>Coreil &#xa0;J, Mayard &#xa0;G, Louis-Charles &#xa0;J, et al. &#xa0;Filarial elephantiasis among Haitian women: Social context and behavioural factors in treatment. Trop Med Int Health. 1998;3(6):467&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">9657509</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammie &#xa0;PJ, Addiss &#xa0;DG, Leonard &#xa0;G, et al. &#xa0;Heterogeneity in filarial-specific immune responsiveness among patients with lymphatic obstruction. J Infect Dis. 1993;167(5):1178&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">8486952</ArticleId></ArticleIdList></Reference><Reference><Citation>Koschorke &#xa0;M, Al-Haboubi &#xa0;YH, Tseng &#xa0;P-C, et al. &#xa0;Mental health, stigma, and neglected tropical diseases: A review and systematic mapping of the evidence. Front Trop Dis. 2022;3:808955.</Citation></Reference><Reference><Citation>van't Noordende &#xa0;AT, Wubie Aycheh &#xa0;M, Tadesse &#xa0;T, et al. &#xa0;A family-based intervention for prevention and self-management of disabilities due to leprosy, podoconiosis and lymphatic filariasis in Ethiopia: A proof of concept study. PLoS Negl Trop Dis. 2021;15(2):e0009167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7924793</ArticleId><ArticleId IdType="pubmed">33600453</ArticleId></ArticleIdList></Reference><Reference><Citation>Dellar &#xa0;R, Ali &#xa0;O, Kinfe &#xa0;M, et al. &#xa0;Effect of a community-based holistic care package on physical and psychosocial outcomes in people with lower limb disorder caused by lymphatic filariasis, podoconiosis, and leprosy in Ethiopia: Results from the EnDPoINT pilot cohort study. Am J Trop Med Hyg. 2022;107(3):624&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9490655</ArticleId><ArticleId IdType="pubmed">35895351</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap &#xa0;JM, Tantono &#xa0;N, Wu &#xa0;VX, Klainin-Yobas P. Effectiveness of technology-based psychosocial interventions on diabetes distress and health-relevant outcomes among type 2 diabetes mellitus: A systematic review and meta-analysis. J Telemed Telecare. 2021;30(2):262&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">34825839</ArticleId></ArticleIdList></Reference><Reference><Citation>Sesel &#xa0;AL, Sharpe &#xa0;L, Naismith &#xa0;SL. &#xa0;Efficacy of psychosocial interventions for people with multiple sclerosis: a meta-analysis of specific treatment effects. Psychother Psychosom. 2018;87(2):105&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">29518781</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorig &#xa0;KR, Sobel &#xa0;DS, Ritter &#xa0;PL, et al. &#xa0;Effect of a self-management program on patients with chronic disease. Eff Clin Pract. 2001;4(6):256&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">11769298</ArticleId></ArticleIdList></Reference><Reference><Citation>Idler &#xa0;EL, Angel &#xa0;RJ. &#xa0;Self-rated health and mortality in the NHANES-I epidemiologic follow-up study. Am J Public Health. 1990;80(4):446&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1404567</ArticleId><ArticleId IdType="pubmed">2316767</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen &#xa0;A, Eustache &#xa0;E, Raviola &#xa0;G, et al. &#xa0;Development and validation of a Haitian creole screening instrument for depression. Transcult Psychiatry. 2015;52:33&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4312265</ArticleId><ArticleId IdType="pubmed">25080426</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimet &#xa0;GD, Dahlem &#xa0;NW, Zimet &#xa0;SG, et al. &#xa0;The Multidimensional scale of perceived social support. J Pers Assess. 1988;52(1):30&#x2013;41.</Citation></Reference><Reference><Citation>Finlay &#xa0;AY, Khan &#xa0;GK. &#xa0;Dermatology Life Quality Index (DLQI)&#x2013;a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8033378</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritter &#xa0;PL, Ory &#xa0;MG, Laurent &#xa0;DD, et al. &#xa0;Effects of chronic disease self-management programs for participants with higher depression scores: Secondary analyses of an on-line and a small-group program. Transl Behav Med. 2014;4(4):398&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4286546</ArticleId><ArticleId IdType="pubmed">25584089</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim &#xa0;SH, Youn &#xa0;CH. &#xa0;Efficacy of chronic disease self-management program in older Korean adults with low and high health literacy. Asian Nursing Research. 2015;9(1):42&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25829209</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorig &#xa0;KR, Ritter &#xa0;PL, Pifer &#xa0;C, et al. &#xa0;Effectiveness of the chronic disease self-management program for persons with a serious mental illness: A translation study. Community Ment Health J. 2014;50:96&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">23748554</ArticleId></ArticleIdList></Reference><Reference><Citation>Santini &#xa0;ZI, Koyanagi &#xa0;A, Tyrovolas &#xa0;S, et al. &#xa0;The association between social relationships and depression: A systematic review. J Affect Disord. 2015;175:53&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">25594512</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang &#xa0;B, Xia &#xa0;L, Yu &#xa0;J, et al. &#xa0;The multiple mediating effects of health literacy and self-care confidence between depression and self-care behaviors in patients with heart failure. Heart Lung. 2020;49(6):842&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">33011463</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen &#xa0;HC, Nguyen &#xa0;MH, Do &#xa0;BN, et al. &#xa0;People with suspected COVID-19 symptoms were more likely depressed and had lower health-related quality of life: the potential benefit of health literacy. J Clin Med. 2020;9(4):965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7231234</ArticleId><ArticleId IdType="pubmed">32244415</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas &#xa0;C, Narahari &#xa0;SR, Bose &#xa0;KS, et al. &#xa0;Comparison of three quality of life instruments in lymphatic filariasis: DLQI, WHODAS 2.0, and LFSQQ. PLoS Negl Trop Dis. 2014;8(2):e2716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3930502</ArticleId><ArticleId IdType="pubmed">24587467</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38380823</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Efficacy of Micronized Purified Flavonoid Fraction in the Posthemorrhoidectomy Period Trial: Open-Label Randomized Controlled Trial.</ArticleTitle><Pagination><StartPage>826</StartPage><EndPage>833</EndPage><MedlinePgn>826-833</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003211</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Frequent early postoperative complications of hemorrhoidectomy are thrombosis and edema of mucocutaneous "bridges."</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to investigate the efficacy of micronized purified flavonoid fraction in preventing complications after elective hemorrhoidectomy.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective unicentral open-label randomized controlled trial.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">2021-2022 at the Clinic of Colorectal and Minimally Invasive Surgery at Sechenov University (Moscow, Russia).</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients who underwent hemorrhoidectomy for grade III and IV hemorrhoids.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">After hemorrhoidectomy, patients were randomly assigned either to standard treatment (peroral nonsteroid anti-inflammatory drugs and local anesthetics, topical steroids, psyllium, warm sitz baths, and nifedipine gel), referred to as the control group, or to standard treatment with micronized purified flavonoid fraction, referred to as the study group, and followed up for 60 days.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Thrombosis or edema of mucocutaneous bridges and pain intensity on a visual analog scale &#x43e;n postoperative days 1-7, 14, 21, and 30; quality of life and patient-assessed treatment effect &#x43e;n postoperative days 1, 3, 7, 21, and 30; and perianal skin tags &#x43e;n postoperative day 60.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The data from 50 patients were analyzed (25 in each group). The visual analog scale demonstrated no differences between groups in each follow-up point. Compared to the control group, the patients in the study group had a significantly higher patient-assessed treatment effect &#x43e;n postoperative days 1, 3, 7, 21, and 30 and a significantly lower rate of thrombosis or edema of mucocutaneous bridges &#x43e;n postoperative days 1-7 and 14. Patients in the study group had significantly lower rates of perianal skin tags.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Unicenter open-label design.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Micronized purified flavonoid fraction in the posthemorrhoidectomy period is an effective adjunct to standard treatment that helps reduce the rate of thrombosis and edema of mucocutaneous bridges, improves patient-assessed treatment effect, and prevents postoperative perianal skin tags formation. Micronized purified flavonoid fraction in the posthemorrhoidectomy period is not associated with additional pain relief in comparison with nonmicronized purified flavonoid fraction standard treatment. See Video Abstract .</AbstractText><AbstractText Label="EFICACIA DE LA FRACCIN DE FLAVONOIDES PURIFICADA MICRONIZADA EN EL PERODO POSTERIOR A LA HEMORROIDECTOMA ENSAYO MOST ENSAYO CONTROLADO, ALEATORIZADO, ABIERTO" NlmCategory="UNASSIGNED">ANTECEDENTES:Una complicaci&#xf3;n postoperatoria temprana frecuente de la hemorroidectom&#xed;a es la trombosis y el edema de los "puentes" mucocut&#xe1;neos.OBJETIVO:Investigamos la eficacia de la fracci&#xf3;n de flavonoides purificada micronizada en la prevenci&#xf3;n de complicaciones despu&#xe9;s de una hemorroidectom&#xed;a electiva.DISE&#xd1;O:Ensayo controlado aleatorio, prospectivo, unicentral, abierto.AJUSTES:2021-2022 Cl&#xed;nica de Cirug&#xed;a Colorrectal y M&#xed;nimamente Invasiva Universidad Sechenov (Mosc&#xfa;, Rusia).PACIENTES:Pacientes despu&#xe9;s de hemorroidectom&#xed;a, que se realiz&#xf3; para hemorroides de grado III-IV.INTERVENCIONES:Despu&#xe9;s de la hemorroidectom&#xed;a, los pacientes fueron asignados aleatoriamente al tratamiento est&#xe1;ndar (antiinflamatorios no esteroides perorales y anest&#xe9;sicos locales, esteroides t&#xf3;picos, psyllium, ba&#xf1;os de asiento tibios, gel de nifedipina) - grupo de control, o al tratamiento est&#xe1;ndar con flavonoide purificado micronizado. fracci&#xf3;n (grupo de estudio) y seguido durante 60 d&#xed;as.RESULTADOS DE MEDIDAS PRINCIPALES:Trombosis o edema de puentes mucocut&#xe1;neos e intensidad del dolor en una escala anal&#xf3;gica visual entre el 1.&#xba;, 7.&#xba;, 14.&#xba;, 21.&#xba; y 30.&#xba; d&#xed;a postoperatorio; calidad de vida y efecto del tratamiento evaluado por el paciente el d&#xed;a 1, 3, 7, 21 y 30 del postoperatorio; Marcas cut&#xe1;neas perianales en el d&#xed;a 60 del postoperatorio.RESULTADOS:Se analizaron los datos de 50 pacientes (25 en cada grupo). La escala anal&#xf3;gica visual no demostr&#xf3; diferencias entre grupos en cada punto de seguimiento. En comparaci&#xf3;n con el grupo de control, los pacientes en el grupo de estudio tuvieron un efecto del tratamiento evaluado por el paciente significativamente mayor en los d&#xed;as 1, 3, 7, 21 y 30 despu&#xe9;s de la operaci&#xf3;n, una tasa significativamente menor de trombosis o edema de los puentes mucocut&#xe1;neos en los d&#xed;as 1, 7 y 14.. Los pacientes del grupo de estudio tuvieron tasas significativamente m&#xe1;s bajas de marcas en la piel perianal.LIMITACIONES:Dise&#xf1;o Unicenter de etiqueta abierta.CONCLUSIONES:La fracci&#xf3;n de flavonoides purificada micronizada en el per&#xed;odo posterior a la hemorroidectom&#xed;a es un complemento eficaz del tratamiento est&#xe1;ndar que ayuda a reducir la tasa de trombosis y edema de los puentes mucocut&#xe1;neos, mejora el efecto del tratamiento evaluado por el paciente y previene la formaci&#xf3;n de marcas cut&#xe1;neas perianales posoperatorias. La fracci&#xf3;n de flavonoides purificados micronizados en el per&#xed;odo posterior a la hemorroidectom&#xed;a no se asocia con un alivio adicional del dolor en comparaci&#xf3;n con el tratamiento est&#xe1;ndar con la fracci&#xf3;n de flavonoides purificados no micronizados. (Traducci&#xf3;n-Yesenia Rojas-Khalil ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Medkova</LastName><ForeName>Yuliya Sergeevna</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Clinic of Colorectal and Minimally Invasive Surgery, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tulina</LastName><ForeName>Inna</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-6404-389</Identifier><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Clinic of Colorectal and Minimally Invasive Surgery, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yudina</LastName><ForeName>Valeriya</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Clinic of Colorectal and Minimally Invasive Surgery, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdullaev</LastName><ForeName>Ruslan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Clinic of Colorectal and Minimally Invasive Surgery, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shcherbakova</LastName><ForeName>Vlada</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Clinic of Colorectal and Minimally Invasive Surgery, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novikov</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Heart Rhythm Disorders, Federal State Budget Organization, National Medical Research Center of Cardiology, Ministry of Healthcare of the Russian Federation, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nikonov</LastName><ForeName>Andrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Snegirev Clinic of Obstetrics and Gynecology, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsarkov</LastName><ForeName>Petr</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-7134-6821</Identifier><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Clinic of Colorectal and Minimally Invasive Surgery, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006484" MajorTopicYN="Y">Hemorrhoids</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005419" MajorTopicYN="Y">Flavonoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061865" MajorTopicYN="Y">Hemorrhoidectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010149" MajorTopicYN="N">Pain, Postoperative</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="N">Thrombosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010147" MajorTopicYN="N">Pain Measurement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>3</Day><Hour>18</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>21</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>21</Day><Hour>8</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38380823</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003211</ArticleId><ArticleId IdType="pii">00003453-202406000-00015</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lohsiriwat V. Treatment of hemorrhoids: a coloproctologist&#x2019;s view. World J Gastroenterol. 2015;21:9245&#x2013;9252.</Citation></Reference><Reference><Citation>Du T, Quan S, Dong T, Meng Q. Comparison of surgical procedures implemented in recent years for patients with grade III and IV hemorrhoids: a network meta-analysis. Int J Colorectal Dis. 2019;34:1001&#x2013;1012.</Citation></Reference><Reference><Citation>Simillis C, Thoukididou SN, Slesser AAP, Rasheed S, Tan E, Tekkis PP. Systematic review and network meta-analysis comparing clinical outcomes and effectiveness of surgical treatments for haemorrhoids. Br J Surg. 2015;102:1603&#x2013;1618.</Citation></Reference><Reference><Citation>Aibuedefe B, Kling SM, Philp MM, Ross HM, Poggio JL. An update on surgical treatment of hemorrhoidal disease: a systematic review and meta-analysis. Int J Colorectal Dis. 2021;36:2041&#x2013;2049.</Citation></Reference><Reference><Citation>Davis BR, Lee-Kong SA, Migaly J, Feingold DL, Steele SR. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of hemorrhoids. Dis Colon Rectum. 2018;61:284&#x2013;292.</Citation></Reference><Reference><Citation>Sugimoto T, Tsunoda A, Kano N, Kashiwagura Y, Hirose K-I, Sasaki T. A randomized, prospective, double-blind, placebo-controlled trial of the effect of diltiazem gel on pain after hemorrhoidectomy. World J Surg. 2013;37:2454&#x2013;2457.</Citation></Reference><Reference><Citation>Amoli HA, Notash AY, Shahandashti FJ, Kenari AY, Ashraf H. A randomized, prospective, double-blind, placebo-controlled trial of the effect of topical diltiazem on posthaemorrhoidectomy pain: effect of diltiazem on posthaemorrhoidectomy pain. Colorectal Dis. 2011;13:328&#x2013;332.</Citation></Reference><Reference><Citation>Liu JW, Lin CC, Kiu KT, Wang CY, Tam KW. Effect of glyceryl trinitrate ointment on pain control after hemorrhoidectomy: a meta-analysis of randomized controlled trials. World J Surg. 2016;40:215&#x2013;224.</Citation></Reference><Reference><Citation>Siddiqui MRS, Abraham-Igwe C, Shangumanandan A, Grassi V, Swift I, Abulafi AM. A literature review on the role of chemical sphincterotomy after Milligan&#x2013;Morgan hemorrhoidectomy. Int J Colorectal Dis. 2011;26:685&#x2013;692.</Citation></Reference><Reference><Citation>Hua X, Zhao Y, Zuo H, Liang J. Progress in the treatment of edema after surgery for mixed hemorrhoids. Proc Anticancer Res. 2021;5:102&#x2013;105.</Citation></Reference><Reference><Citation>Tahir M, Rehman MU, Lateef A, et al. Diosmin protects against ethanol-induced hepatic injury via alleviation of inflammation and regulation of TNF-&#x3b1; and NF-&#x3ba;B activation. Alcohol. 2013;47:131&#x2013;139.</Citation></Reference><Reference><Citation>Berk&#xf6;z M. Diosmin suppresses the proinflammatory mediators in lipopolysaccharide-induced RAW264.7 macrophages via NF-&#x3ba;B and MAPKs signal pathways. Gen Physiol Biophys. 2019;38:315&#x2013;324.</Citation></Reference><Reference><Citation>Crespo M, G&#xe1;lvez J, Cruz T, Ocete M, Zarzuelo A. Anti-inflammatory activity of diosmin and hesperidin in rat colitis induced by TNBS. Planta Med. 1999;65:651&#x2013;653.</Citation></Reference><Reference><Citation>Shalkami A, Hassan M, Bakr A. Anti-inflammatory, antioxidant and anti-apoptotic activity of diosmin in acetic acid-induced ulcerative colitis. Hum Exp Toxicol. 2018;37:78&#x2013;86.</Citation></Reference><Reference><Citation>Zieli&#x144;ska-Przyjemska M, Ignatowicz E. Citrus fruit flavonoids influence on neutrophil apoptosis and oxidative metabolism: biological effect of citrus fruit flavonoids. Phytother Res. 2008;22:1557&#x2013;1562.</Citation></Reference><Reference><Citation>Shi X, Liao S, Mi H, et al. Hesperidin prevents retinal and plasma abnormalities in streptozotocin-induced diabetic rats. Molecules. 2012;17:12868&#x2013;12881.</Citation></Reference><Reference><Citation>Qi W, Lin C, Fan K, et al. Hesperidin inhibits synovial cell inflammation and macrophage polarization through suppression of the PI3K/AKT pathway in complete Freund&#x2019;s adjuvant-induced arthritis in mice. Chem Biol Interact. 2019;306:19&#x2013;28.</Citation></Reference><Reference><Citation>Choi IY, Kim SJ, Jeong HJ, et al. Hesperidin inhibits expression of hypoxia inducible factor-1 alpha and inflammatory cytokine production from mast cells. Mol Cell Biochem. 2007;305:153&#x2013;161.</Citation></Reference><Reference><Citation>Orefice R, Litta F, Parello A, et al. A prospective study on the efficacy of two different phlebotonic therapies as a bridge to surgery in patients with advanced hemorrhoidal disease. J Clin Med. 2021;10:1549.</Citation></Reference><Reference><Citation>Godeberge P, Sheikh P, Lohsiriwat V, Jalife A, Shelygin Y. Micronized purified flavonoid fraction in the treatment of hemorrhoidal disease. J Comp Eff Res. 2021;10:801&#x2013;813.</Citation></Reference><Reference><Citation>Alonso-Coello P, Zhou Q, Martinez-Zapata MJ, et al. Meta-analysis of flavonoids for the treatment of haemorrhoids. Br J Surg. 2006;93:909&#x2013;920.</Citation></Reference><Reference><Citation>Rabelo FEF, Lacerda-Filho A, Mansur ES, et al. Benefits of flavonoid and metronidazole use after excisional hemorrhoidectomy: a randomized double-blind clinical trial. Tech Coloproctol. 2021;25:949&#x2013;955.</Citation></Reference><Reference><Citation>La Torre F, Nicolai AP. Clinical use of micronized purified flavonoid fraction for treatment of symptoms after hemorrhoidectomy: results of a randomized, controlled, clinical trial. Dis Colon Rectum. 2004;47:704&#x2013;710.</Citation></Reference><Reference><Citation>Efetov SK, Medkova YS, Kitsenko YE, Ong K, Tulina IA, Tsarkov PV. Step-by-step open excisional haemorrhoidectomy for grade IV circular haemorrhoidal disease&#x2014;a video vignette. Colorectal Dis. 2020;22:1452&#x2013;1453.</Citation></Reference><Reference><Citation>Ware JE, Kosinski M, Keller SDA. 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220&#x2013;233.</Citation></Reference><Reference><Citation>Hoffmann C, McFarland BH, Kinzie JD, et al. Psychometric properties of a Russian version of the SF-12 health survey in a refugee population. Compr Psychiatry. 2005;46:390&#x2013;397.</Citation></Reference><Reference><Citation>Picciariello A, Papagni V, Martines G, De Fazio M, Digennaro R, Altomare DF. Post-operative clinical, manometric, and defecographic findings in patients undergoing unsuccessful STARR operation for obstructed defecation. Int J Colorectal Dis. 2019;34:837&#x2013;842.</Citation></Reference><Reference><Citation>Wang X, Ji X. Sample size estimation in clinical research. Chest. 2020;158:S12&#x2013;S20.</Citation></Reference><Reference><Citation>Perera N, Liolitsa D, Iype S, et al. Phlebotonics for haemorrhoids. Cochrane Database Syst Rev. 2012;8:CD004322.</Citation></Reference><Reference><Citation>Tsarkov P, Medkova Y, Yudina V, et al. The effects of micronized purified flavonoid fraction in post-hemorrhoidectomy period [ASCRS abstract S14]. Dis Colon Rectum. 2023;66:e362&#x2013;e363.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34890373</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Follow-up Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel (Mesenchymal Stem Cell Treatment) in Patients With Perianal Fistulizing Crohn's Disease: ADMIRE-CD Phase 3 Randomized Controlled Trial.</ArticleTitle><Pagination><StartPage>713</StartPage><EndPage>720</EndPage><MedlinePgn>713-720</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002325</ELocationID><Abstract><AbstractText Label="BACKGROUND">Darvadstrocel is an expanded allogeneic adipose-derived mesenchymal stem cell therapy for the treatment of complex perianal fistulas in patients with Crohn's disease. Safety and efficacy outcomes from the clinical trial known as "Adipose derived mesenchymal stem cells for induction of remission in perianal fistulizing Crohn's disease," or ADMIRE-CD (NCT01541579), from up to 52 weeks posttreatment were previously reported. Here, the outcomes from an extended 104-week follow-up are reported.</AbstractText><AbstractText Label="OBJECTIVE">The goal of this study was to assess the long-term safety and efficacy of darvadstrocel at 2 years post-treatment in patients with Crohn's disease and complex perianal fistulas.</AbstractText><AbstractText Label="DESIGN">This was a phase 3 double-blind randomized controlled study (ADMIRE-CD) in patients with perianal fistulizing Crohn's disease.</AbstractText><AbstractText Label="SETTINGS">This study extension was conducted in multiple hospitals across 7 European countries and Israel.</AbstractText><AbstractText Label="PATIENTS">Forty patients entered the extended follow-up period: 25 patients in the darvadstrocel treatment group and 15 in the control group.</AbstractText><AbstractText Label="INTERVENTIONS">Darvadstrocel or saline solution (control group) was administered once, locally, after fistula tract curettage and internal opening closure (with previous seton placement). All patients were permitted to continue ongoing medical treatments for fistulas.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Treatment-emergent serious adverse events were recorded through week 104. Clinical remission, defined as closure of all treated external openings that were draining at baseline despite gentle finger compression, was assessed at week 104.</AbstractText><AbstractText Label="RESULTS">Of 40 patients, 37 completed the extended follow-up. Through week 104, 7 treatment-emergent serious adverse events were reported, of which 4 occurred between weeks 52 and 104. At week 104, clinical remission was reported in 14/25 (56%) patients in the darvadstrocel group and 6/15 (40%) patients in the control group.</AbstractText><AbstractText Label="LIMITATIONS">Limitations include the small number of patients who entered the extended follow-up period, and no imaging examinations were performed at the 104-week time point.</AbstractText><AbstractText Label="CONCLUSIONS">Darvadstrocel was well tolerated and clinical remission after treatment with darvadstrocel may be sustained for up to 104 weeks in patients with perianal fistulizing Crohn's disease. See Video Abstract at http://links.lww.com/DCR/B812.ClinicalTrials.gov No: NCT01541579.</AbstractText><AbstractText Label="ESTUDIO DE SEGUIMIENTO PARA EVALUAR LA SEGURIDAD Y EFICACIA A LARGO PLAZO DE DARVADSTROCEL TRATAMIENTO CON CLULAS MADRE MESENQUIMALES EN PACIENTES CON ENFERMEDAD DE CROHN PERIANAL FISTULIZANTE ENSAYO CONTROLADO ALEATORIZADO DE FASE ADMIRECD">ANTECEDENTES:Darvadstrocel es una terapia con c&#xe9;lulas madre mesenquimales alog&#xe9;nicas expandidas derivadas de tejido adiposo para el tratamiento de f&#xed;stulas perianales complejas en pacientes con enfermedad de Crohn. Los resultados del ensayo cl&#xed;nico conocido como "C&#xe9;lulas madre mesenquimales derivadas de tejido adiposo para la inducci&#xf3;n de la remisi&#xf3;n en la enfermedad de Crohn fistulizante perianal" o ADMIRE-CD (NCT01541579), en cuanto a la seguridad y eficacia hasta 52 semanas despu&#xe9;s del tratamiento, fueron previamente informados. Seguidamente, se presentan los resultados de un seguimiento extendido de 104 semanas.OBJETIVO:Evaluar la seguridad y eficacia a largo plazo de darvadstrocel a dos a&#xf1;os del tratamiento en pacientes con enfermedad de Crohn y f&#xed;stulas perianales complejas.DISE&#xd1;O:Este fue un estudio de fase 3, aleatorizado, a doble ciego, controlado (ADMIRE-CD) en pacientes con enfermedad de Crohn perianal fistulizante.DESARROLLO:Esta extensi&#xf3;n del estudio se realiz&#xf3; en varios hospitales de siete pa&#xed;ses europeos e Israel.PACIENTES:Cuarenta pacientes participaron en la extensi&#xf3;n de seguimiento: tratamiento con darvadstrocel (n = 25); grupo control (n = 15).INTERVENCIONES:Se administr&#xf3; Darvadstrocel o soluci&#xf3;n salina (grupo control) una vez, localmente, tras el legrado del trayecto f&#xed;stuloso y cierre del orificio interno (con la colocaci&#xf3;n previa de set&#xf3;n). A todos los pacientes se les permiti&#xf3; continuar con los tratamientos m&#xe9;dicos en curso para las f&#xed;stulas.PRINCIPALES MEDIDAS DE RESULTADO:Los eventos de efectos adversos graves derivados del tratamiento se registraron hasta la semana 104. La remisi&#xf3;n cl&#xed;nica, definida como el cierre de todas las aberturas externas tratadas que drenaban al inicio espont&#xe1;neamente o por compresi&#xf3;n suave de los dedos, fue evaluado en la semana 104.RESULTADOS:Del total de 40 pacientes, 37 completaron la extensi&#xf3;n de seguimiento. Hasta la semana 104, se reportaron 7 eventos de efectos adversos graves resultantes del tratamiento, de los cuales 4 ocurrieron entre las semanas 52 y 104. En la semana 104, se report&#xf3; remisi&#xf3;n cl&#xed;nica en 14/25 (56%) pacientes en el grupo de darvadstrocel y 6/15 (40%) pacientes en el grupo de control.LIMITACIONES:Solo una peque&#xf1;a cantidad de pacientes participaron en el per&#xed;odo de seguimiento extendido y no se realizaron ex&#xe1;menes por t&#xe9;cnicas de imagen en la visita a 104 semanas.CONCLUSIONES:Darvadstrocel fue bien tolerado y la remisi&#xf3;n cl&#xed;nica despu&#xe9;s del tratamiento con darvadstrocel puede mantenerse hasta 104 semanas en pacientes con enfermedad de Crohn perianal fistulizante. Consulte Video Resumen en http://links.lww.com/DCR/B812. (Traducci&#xf3;n-Dr Osvaldo Gauto and Dr Julian Pan&#xe9;s.)ClinicalTrials.gov No. NCT01541579.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Colon and Rectal Surgeons.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garcia-Olmo</LastName><ForeName>Dami&#xe1;n</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Universidad Aut&#xf3;noma de Madrid, Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, University Hospital, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilaberte</LastName><ForeName>Inmaculada</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Takeda Pharmaceuticals S.L., Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binek</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Takeda Pharmaceuticals International AG, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D Hoore</LastName><ForeName>Andr&#xe9; J L</ForeName><Initials>AJL</Initials><AffiliationInfo><Affiliation>Universitair Ziekenhuis Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindner</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Takeda Pharmaceuticals International AG, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selvaggi</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Colon and Rectal Surgery Unit, Department of Advanced Medical and Surgery Sciences, Luigi Vanvitelli University, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spinelli</LastName><ForeName>Antonino</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, Division of Colon and Rectal Surgery, Rozzano Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan&#xe9;s</LastName><ForeName>Julian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Inflammatory Bowel Disease Unit, Hospital Cl&#xed;nic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01541579</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="Y">Crohn Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059630" MajorTopicYN="Y">Mesenchymal Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033581" MajorTopicYN="N">Stem Cell Transplantation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>10</Day><Hour>17</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34890373</ArticleId><ArticleId IdType="pmc">PMC8985696</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002325</ArticleId><ArticleId IdType="pii">00003453-202205000-00016</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baumgart DC, Sandborn WJ. Crohn&#x2019;s disease. Lancet. 2012;380:1590&#x2013;1605.</Citation><ArticleIdList><ArticleId IdType="pubmed">22914295</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB; American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn&#x2019;s disease. Gastroenterology. 2003;125:1508&#x2013;1530.</Citation><ArticleIdList><ArticleId IdType="pubmed">14598268</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaparro M, Burgueno P, Vera I, et al. . Epidemiological study of perianal fistulas in patients with Crohn&#x2019;s disease. Gastroenterology. 2011;140:S736.</Citation></Reference><Reference><Citation>Kasparek MS, Glatzle J, Temeltcheva T, Mueller MH, Koenigsrainer A, Kreis ME. Long-term quality of life in patients with Crohn&#x2019;s disease and perianal fistulas: influence of fecal diversion. Dis Colon Rectum. 2007;50:2067&#x2013;2074.</Citation><ArticleIdList><ArticleId IdType="pubmed">17680311</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilera-Castro L, Ferre-Aracil C, Garcia-Garcia-de-Paredes A, Rodriguez-de-Santiago E, Lopez-Sanroman A. Management of complex perianal Crohn&#x2019;s disease. Ann Gastroenterol.2017;30:33&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5198245</ArticleId><ArticleId IdType="pubmed">28042236</ArticleId></ArticleIdList></Reference><Reference><Citation>Adegbola SO, Dibley L, Sahnan K, et al. . Burden of disease and adaptation to life in patients with Crohn&#x2019;s perianal fistula: a qualitative exploration. Health Qual Life Outcomes. 2020;18:370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7678264</ArticleId><ArticleId IdType="pubmed">33218361</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz DA, Loftus EV, Jr, Tremaine WJ, et al. . The natural history of fistulizing Crohn&#x2019;s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pubmed">11910338</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz DA, Tagarro I, Carmen D&#xed;ez M, Sandborn WJ. Prevalence of fistulizing Crohn&#x2019;s disease in the United States: estimate from a systematic literature review attempt and population-based database analysis. Inflamm Bowel Dis. 2019;25:1773&#x2013;1779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6799946</ArticleId><ArticleId IdType="pubmed">31216573</ArticleId></ArticleIdList></Reference><Reference><Citation>Eglinton TW, Barclay ML, Gearry RB, Frizelle FA. The spectrum of perianal Crohn&#x2019;s disease in a population-based cohort. Dis Colon Rectum. 2012;55:773&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pubmed">22706129</ArticleId></ArticleIdList></Reference><Reference><Citation>Panes J, Reinisch W, Rupniewska E, et al. . Burden and outcomes for complex perianal fistulas in Crohn&#x2019;s disease: Systematic review. World J Gastroenterol. 2018;24:4821&#x2013;4834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6235801</ArticleId><ArticleId IdType="pubmed">30479468</ArticleId></ArticleIdList></Reference><Reference><Citation>Present DH, Rutgeerts P, Targan S, et al. . Infliximab for the treatment of fistulas in patients with Crohn&#x2019;s disease. N Engl J Med. 1999;340:1398&#x2013;1405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10228190</ArticleId></ArticleIdList></Reference><Reference><Citation>Sands BE, Anderson FH, Bernstein CN, et al. . Infliximab maintenance therapy for fistulizing Crohn&#x2019;s disease. N Engl J Med. 2004;350:876&#x2013;885.</Citation><ArticleIdList><ArticleId IdType="pubmed">14985485</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres J, Bonovas S, Doherty G, et al. . ECCO Guidelines on Therapeutics in Crohn&#x2019;s Disease: Medical Treatment. J Crohns Colitis. 2020;14:4&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">31711158</ArticleId></ArticleIdList></Reference><Reference><Citation>Gionchetti P, Dignass A, Danese S, et al. .; ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn&#x2019;s Disease 2016: Part 2: Surgical Management and Special Situations. J Crohns Colitis. 2017;11:135&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">27660342</ArticleId></ArticleIdList></Reference><Reference><Citation>Ardizzone S, Maconi G, Colombo E, Manzionna G, Bollani S, Bianchi Porro G. Perianal fistulae following infliximab treatment: clinical and endosonographic outcome. Inflamm Bowel Dis. 2004;10:91&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">15168807</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton C, Dibley LB, Bassett P. Faecal incontinence in inflammatory bowel disease: associations and effect on quality of life. J Crohns Colitis. 2013;7:e302&#x2013;e311.</Citation><ArticleIdList><ArticleId IdType="pubmed">23228710</ArticleId></ArticleIdList></Reference><Reference><Citation>Gecse KB, Bemelman W, Kamm MA, et al. .; World Gastroenterology Organization, International Organisation for Inflammatory Bowel Diseases IOIBD, European Society of Coloproctology and Robarts Clinical Trials; World Gastroenterology Organization International Organisation for Inflammatory Bowel Diseases IOIBD European Society of Coloproctology and Robarts Clinical Trials. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn&#x2019;s disease. Gut. 2014;63:1381&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">24951257</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Olmo D, Garc&#xed;a-Arranz M, Herreros D, Pascual I, Peiro C, Rodr&#xed;guez-Montes JA. A phase I clinical trial of the treatment of Crohn&#x2019;s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48:1416&#x2013;1423.</Citation><ArticleIdList><ArticleId IdType="pubmed">15933795</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Portilla F, Alba F, Garc&#xed;a-Olmo D, Herrer&#xed;as JM, Gonz&#xe1;lez FX, Galindo A. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn&#x2019;s disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis. 2013;28:313&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">23053677</ArticleId></ArticleIdList></Reference><Reference><Citation>Scharl M, Rogler G. Pathophysiology of fistula formation in Crohn&#x2019;s disease. World J Gastrointest Pathophysiol. 2014;5:205&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4133520</ArticleId><ArticleId IdType="pubmed">25133023</ArticleId></ArticleIdList></Reference><Reference><Citation>DelaRosa O, Dalemans W, Lombardo E. Mesenchymal stem cells as therapeutic agents of inflammatory and autoimmune diseases. Curr Opin Biotechnol. 2012;23:978&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pubmed">22682584</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan&#xe9;s J, Garc&#xed;a-Olmo D, Van Assche G, et al. .; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn&#x2019;s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388:1281&#x2013;1290.</Citation><ArticleIdList><ArticleId IdType="pubmed">27477896</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan&#xe9;s J, Garc&#xed;a-Olmo D, Van Assche G, et al. .; ADMIRE CD Study Group Collaborators. Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn&#x2019;s disease. Gastroenterology. 2018;154:1334&#x2013;1342.e4.</Citation><ArticleIdList><ArticleId IdType="pubmed">29277560</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamina M, Bonovas S, Raine T, et al. . ECCO Guidelines on Therapeutics in Crohn&#x2019;s Disease: Surgical Treatment. J Crohns Colitis. 2020;14:155&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">31742338</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabalzar-Wondberg D, Turina M, Biedermann L, Rogler G, Schreiner P. Allogeneic expanded adipose-derived mesenchymal stem cell therapy for perianal fistulas in Crohn&#x2019;s disease: a case series. Colorectal Dis. 2021;23:1444&#x2013;1450.</Citation><ArticleIdList><ArticleId IdType="pubmed">33595166</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez N, Ramamoorthy S, Sandborn WJ. Recent advances in the management of perianal fistulizing Crohn&#x2019;s disease: lessons for the clinic. Expert Rev Gastroenterol Hepatol. 2019;13:563&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6545251</ArticleId><ArticleId IdType="pubmed">31023087</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenstein GR, Feagan BG, Cohen RD, et al. . Infliximab for Crohn&#x2019;s disease: more than 13 years of real-world experience. Inflamm Bowel Dis. 2018;24:490&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6176880</ArticleId><ArticleId IdType="pubmed">29462395</ArticleId></ArticleIdList></Reference><Reference><Citation>Zmora O, Pan&#xe9;s J, Drohan C, et al. . P491 inspire: design and implementation aspects of a registry of complex perianal fistulas in crohn&#x2019;s disease patients treated with darvadstrocel. J Crohn&#x2019;s Colitis. 2019;13(suppl 1):S357&#x2013;S358.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34747917</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Botulinum Toxin Injection Plus Topical Diltiazem for Chronic Anal Fissure: A Randomized Double-Blind Clinical Trial and Long-term Outcome.</ArticleTitle><Pagination><StartPage>1521</StartPage><EndPage>1530</EndPage><MedlinePgn>1521-1530</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000001983</ELocationID><Abstract><AbstractText Label="BACKGROUND">Chemical sphincterotomy avoids the risk of permanent incontinence in the treatment of chronic anal fissure, but it does not reach the efficacy of surgery and recurrence is high. Drug combination has been proposed to overcome these drawbacks.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to compare the clinical, morphological, and functional effects of combined therapy with botulinum toxin injection and topical diltiazem in chronic anal fissure and to assess the long-term outcome after healing.</AbstractText><AbstractText Label="DESIGN">This is a randomized, controlled, double-blind, 2-arm, parallel-group trial with a long-term follow-up.</AbstractText><AbstractText Label="SETTINGS">This study was conducted at a tertiary care center.</AbstractText><AbstractText Label="PATIENTS">A total of 70 consecutive patients were referred to the gastroenterology department of a hospital in Valencia, Spain.</AbstractText><AbstractText Label="INTERVENTION">After botulinum toxin injection (20 IU), patients were randomly assigned to local diltiazem (diltiazem group) or placebo gel (placebo group) for 12 weeks.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The primary outcome was fissure healing (evaluated by video register by 3 independent physicians). Secondary outcomes included symptomatic relief (30-day diary), effect on anal sphincters (manometry), safety, and long-term recurrence (24 months and 10 years).</AbstractText><AbstractText Label="RESULTS">Healing was achieved per protocol in 13 of 25 (52%) patients of the diltiazem group and 11 of 30 (36.7%) patients of the placebo group (p = 0.25); on an intention-to-treat basis in 37.1% and 31.4% (p = 0.61). Both groups displayed significant reduction of anal pressures. Thirty percent reported minor and transitory incontinence, without differences between groups. Nine (69.2%) of the diltiazem group and 6 (54.5%) of the placebo group experienced a relapse at 24 months (p = 0.67). The overall recurrence rate at 10 years was 83.3% (20/24 patients).</AbstractText><AbstractText Label="LIMITATIONS">This study was limited by the loss of patients during the trial. The low healing rate led to a small cohort to assess recurrence.</AbstractText><AbstractText Label="CONCLUSIONS">Combined botulinum toxin injection and topical diltiazem is not superior to botulinum toxin injection in the treatment of chronic anal fissure. Both options offer suboptimal healing rates. Long-term recurrence is high (&gt;80% at 10 years) and might appear at any time after healing. See Video Abstract at http://links.lww.com/DCR/B527.</AbstractText><AbstractText Label="INYECCIN DE TOXINA BOTULNICA MS DILTIAZEM TPICO EN FISURA ANAL CRNICA UN ENSAYO CLNICO ALEATORIZADO DOBLE CIEGO Y RESULTADOS A LARGO PLAZO">ANTECEDENTES:La esfinterotom&#xed;a qu&#xed;mica evita el riesgo de incontinencia permanente en el tratamiento de la fisura anal cr&#xf3;nica, pero no alcanza la eficacia de la cirug&#xed;a y la recurrencia es alta. Se ha propuesto la combinaci&#xf3;n de f&#xe1;rmacos para superar estos inconvenientes.OBJETIVO:Comparar los efectos cl&#xed;nicos, morfol&#xf3;gicos y funcionales de la terapia combinada con inyecci&#xf3;n de toxina botul&#xed;nica y diltiazem t&#xf3;pico en fisura anal cr&#xf3;nica y evaluar el resultado a largo plazo despu&#xe9;s de la cicatrizaci&#xf3;n.DISE&#xd1;O:Ensayo aleatorizado, controlado, doble ciego, de dos brazos, de grupos paralelos con un seguimiento a largo plazo.ESCENARIO:Estudio realizado en un centro de atenci&#xf3;n terciaria.PACIENTES:Un total de 70 pacientes consecutivos referidos al servicio de gastroenterolog&#xed;a de un hospital de Valencia, Espa&#xf1;a.INTERVENCI&#xd3;N:Despu&#xe9;s de la inyecci&#xf3;n de toxina botul&#xed;nica (20UI), los pacientes fueron asignados al azar a diltiazem local (grupo de diltiazem) o gel de placebo (grupo de placebo) durante 12 semanas.PRINCIPALES MEDIDAS DE RESULTADO:El resultado primario fue la cicatrizaci&#xf3;n de la fisura (evaluado por registro de video por tres m&#xe9;dicos independientes). Los resultados secundarios incluyeron alivio sintom&#xe1;tico (diario de 30 d&#xed;as), efecto sobre los esf&#xed;nteres anales (manometr&#xed;a), seguridad y recurrencia a largo plazo (24 meses y 10 a&#xf1;os).RESULTADOS:La curaci&#xf3;n se logr&#xf3; por protocolo en 13/25 (52%) en el grupo de Diltiazem y 11/30 (36,7%) en el grupo de Placebo (p = 0.25); por intenci&#xf3;n de tratar en el 37.1% y el 31.4%, respectivamente (p = 0.61). Ambos grupos mostraron una reducci&#xf3;n significativa de las presiones anales. El 30% refiri&#xf3; incontinencia leve y transitoria, sin diferencias entre grupos. 9 (69.2%) del grupo de Diltiazem y 6 (54.5%) del grupo de placebo recurrieron a los 24 meses (p = 0.67). La tasa global de recurrencia a los 10 a&#xf1;os fue del 83.3% (20/24 pacientes).LIMITACIONES:La p&#xe9;rdida de pacientes a lo largo del ensayo. La baja tasa de curaci&#xf3;n llev&#xf3; a una peque&#xf1;a cohorte para evaluar la recurrencia.CONCLUSIONES:La inyecci&#xf3;n combinada de toxina botul&#xed;nica y diltiazem t&#xf3;pico no es superior a la inyecci&#xf3;n de TB en el tratamiento de la fisura anal cr&#xf3;nica. Ambas opciones ofrecen tasas de curaci&#xf3;n sub&#xf3;ptimas. La recurrencia a largo plazo es alta (&gt; 80% a los 10 a&#xf1;os) y puede aparecer en cualquier momento despu&#xe9;s de la curaci&#xf3;n. Consulte Video Resumen en http://links.lww.com/DCR/B527.</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herreros</LastName><ForeName>Belen</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hospital de Villajoyosa, Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espi</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Hospital Cl&#xed;nico Universitario, University of Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mont&#xf3;n Rodriguez</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hospital Cl&#xed;nico Universitario, University of Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Granero</LastName><ForeName>Eduardo Garc&#xed;a-</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Digestive Surgery Unit, Department of General Surgery, Hospital Universitario y Politecnico La Fe, University of Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchiz</LastName><ForeName>Vicente</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Hospital Cl&#xed;nico Universitario de Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferriols</LastName><ForeName>Francisco L</ForeName><Initials>FL</Initials><AffiliationInfo><Affiliation>Gastroenterology Department, Hospital General Universitario de Castell&#xf3;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almela</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Complexo Hospitalario Universitario de Vigo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Vicente</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Complexo Hospitalario Universitario de Vigo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mora</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Hospital Cl&#xed;nico Universitario de Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xed;nguez</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Hospital Cl&#xed;nico Universitario de Valencia, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D057405">Webcast</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009498">Neurotoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.69</RegistryNumber><NameOfSubstance UI="D001905">Botulinum Toxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EE92BBP03H</RegistryNumber><NameOfSubstance UI="D004110">Diltiazem</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Dis Colon Rectum. 2022 May 1;65(5):e339. doi: 10.1097/DCR.0000000000002434.</RefSource><PMID Version="1">35185134</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Dis Colon Rectum. 2022 May 1;65(5):e340. doi: 10.1097/DCR.0000000000002435.</RefSource><PMID Version="1">35185136</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000287" MajorTopicYN="N">Administration, Topical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001003" MajorTopicYN="N">Anal Canal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001905" MajorTopicYN="N">Botulinum Toxins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004110" MajorTopicYN="N">Diltiazem</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005401" MajorTopicYN="N">Fissure in Ano</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007267" MajorTopicYN="N">Injections</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008365" MajorTopicYN="N">Manometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009498" MajorTopicYN="N">Neurotoxins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062606" MajorTopicYN="N">Tertiary Care Centers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014945" MajorTopicYN="N">Wound Healing</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>8</Day><Hour>12</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34747917</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000001983</ArticleId><ArticleId IdType="pii">00003453-202112000-00013</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brisinda G, Maria G, Bentivoglio AR, Cassetta E, Gui D, Albanese A. A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. N Engl J Med. 1999;341:65&#x2013;69.</Citation></Reference><Reference><Citation>M&#xed;nguez M, Melo F, Esp&#xed; A, et al. Therapeutic effects of different doses of botulinum toxin in chronic anal fissure. Dis Colon Rectum. 1999;42:1016&#x2013;1021.</Citation></Reference><Reference><Citation>Brisinda G, Maria G, Sganga G, Bentivoglio AR, Albanese A, Castagneto M. Effectiveness of higher doses of botulinum toxin to induce healing in patients with chronic anal fissures. Surgery. 2002;131:179&#x2013;184.</Citation></Reference><Reference><Citation>Lund JN, Scholefield JH. A randomised, prospective, double-blind, placebo-controlled trial of glyceryl trinitrate ointment in treatment of anal fissure. Lancet. 1997;349:11&#x2013;14.</Citation></Reference><Reference><Citation>Kennedy ML, Sowter S, Nguyen H, Lubowski DZ. Glyceryl trinitrate ointment for the treatment of chronic anal fissure: results of a placebo-controlled trial and long-term follow-up. Dis Colon Rectum. 1999;42:1000&#x2013;1006.</Citation></Reference><Reference><Citation>Altomare DF, Rinaldi M, Milito G, et al. Glyceryl trinitrate for chronic anal fissure&#x2013;healing or headache? Results of a multicenter, randomized, placebo-controled, double-blind trial. Dis Colon Rectum. 2000;43:174&#x2013;179.</Citation></Reference><Reference><Citation>Scholefield JH, Bock JU, Marla B, et al. A dose finding study with 0.1%, 0.2%, and 0.4% glyceryl trinitrate ointment in patients with chronic anal fissures. Gut. 2003;52:264&#x2013;269.</Citation></Reference><Reference><Citation>Kocher HM, Steward M, Leather AJ, Cullen PT. Randomized clinical trial assessing the side-effects of glyceryl trinitrate and diltiazem hydrochloride in the treatment of chronic anal fissure. Br J Surg. 2002;89:413&#x2013;417.</Citation></Reference><Reference><Citation>Bielecki K, Kolodziejczak M. A prospective randomized trial of diltiazem and glyceryltrinitrate ointment in the treatment of chronic anal fissure. Colorectal Dis. 2003;5:256&#x2013;257.</Citation></Reference><Reference><Citation>Samim M, Twigt B, Stoker L, Pronk A. Topical diltiazem cream versus botulinum toxin a for the treatment of chronic anal fissure: a double-blind randomized clinical trial. Ann Surg. 2012;255:18&#x2013;22.</Citation></Reference><Reference><Citation>Shrivastava UK, Jain BK, Kumar P, Saifee Y. A comparison of the effects of diltiazem and glyceryl trinitrate ointment in the treatment of chronic anal fissure: a randomized clinical trial. Surg Today. 2007;37:482&#x2013;485.</Citation></Reference><Reference><Citation>Sajid MS, Whitehouse PA, Sains P, Baig MK. Systematic review of the use of topical diltiazem compared with glyceryltrinitrate for the nonoperative management of chronic anal fissure. Colorectal Dis. 2013;15:19&#x2013;26.</Citation></Reference><Reference><Citation>Sajid MS, Rimple J, Cheek E, Baig MK. The efficacy of diltiazem and glyceryltrinitrate for the medical management of chronic anal fissure: a meta-analysis. Int J Colorectal Dis. 2008;23:1&#x2013;6.</Citation></Reference><Reference><Citation>Jost WH. Ten years&#x2019; experience with botulin toxin in anal fissure. Int J Colorectal Dis. 2002;17:298&#x2013;302.</Citation></Reference><Reference><Citation>Minguez M, Herreros B, Espi A, et al. Long-term follow-up (42 months) of chronic anal fissure after healing with botulinum toxin. Gastroenterology. 2002;123:112&#x2013;117.</Citation></Reference><Reference><Citation>Arroyo A, Perez F, Serrano P, Candela F, Calpena R. Long-term results of botulinum toxin for the treatment of chronic anal fissure: prospective clinical and manometric study. Int J Colorectal Dis. 2005;20:267&#x2013;271.</Citation></Reference><Reference><Citation>Sileri P, Stolfi VM, Franceschilli L, et al. Conservative and surgical treatment of chronic anal fissure: prospective longer term results. J Gastrointest Surg. 2010;14:773&#x2013;780.</Citation></Reference><Reference><Citation>Pitt J, Williams S, Dawson PM. Reasons for failure of glyceryl trinitrate treatment of chronic fissure-in-ano: a multivariate analysis. Dis Colon Rectum. 2001;44:864&#x2013;867.</Citation></Reference><Reference><Citation>Parellada C. Randomized, prospective trial comparing 0.2 percent isosorbide dinitrate ointment with sphincterotomy in treatment of chronic anal fissure: a two-year follow-up. Dis Colon Rectum. 2004;47:437&#x2013;443.</Citation></Reference><Reference><Citation>Jonas M, Lund JN, Scholefield JH. Topical 0.2% glyceryl trinitrate ointment for anal fissures: long-term efficacy in routine clinical practice. Colorectal Dis. 2002;4:317&#x2013;320.</Citation></Reference><Reference><Citation>Graziano A, Svidler L&#xf3;pez L, Lencinas S, Masciangioli G, Gualdrini U, Bisisio O. Long-term results of topical nitroglycerin in the treatment of chronic anal fissures are disappointing. Tech Coloproctol. 2001;5:143&#x2013;147.</Citation></Reference><Reference><Citation>Nash GF, Kapoor K, Saeb-Parsy K, Kunanadam T, Dawson PM. The long-term results of diltiazem treatment for anal fissure. Int J Clin Pract. 2006;60:1411&#x2013;1413.</Citation></Reference><Reference><Citation>Abcarian H, Lakshmanan S, Read DR, Roccaforte P. The role of internal sphincter in chronic anal fissures. Dis Colon Rectum. 1982;25:525&#x2013;528.</Citation></Reference><Reference><Citation>Garcia-Aguilar J, Belmonte C, Wong WD, Lowry AC, Madoff RD. Open vs. closed sphincterotomy for chronic anal fissure: long-term results. Dis Colon Rectum. 1996;39:440&#x2013;443.</Citation></Reference><Reference><Citation>Nyam DC, Pemberton JH. Long-term results of lateral internal sphincterotomy for chronic anal fissure with particular reference to incidence of fecal incontinence. Dis Colon Rectum. 1999;42:1306&#x2013;1310.</Citation></Reference><Reference><Citation>Poh A, Tan KY, Seow-Choen F. Innovations in chronic anal fissure treatment: a systematic review. World J Gastrointest Surg. 2010;2:231&#x2013;241.</Citation></Reference><Reference><Citation>Nelson RL, Thomas K, Morgan J, Jones A. Non surgical therapy for anal fissure. Cochrane Database Syst Rev. 2012;2012:CD003431.</Citation></Reference><Reference><Citation>Lysy J, Israelit-Yatzkan Y, Sestiery-Ittah M, Weksler-Zangen S, Keret D, Goldin E. Topical nitrates potentiate the effect of botulinum toxin in the treatment of patients with refractory anal fissure. Gut. 2001;48:221&#x2013;224.</Citation></Reference><Reference><Citation>Jones OM, Ramalingam T, Merrie A, et al. Randomized clinical trial of botulinum toxin plus glyceryl trinitrate vs. botulinum toxin alone for medically resistant chronic anal fissure: overall poor healing rates. Dis Colon Rectum. 2006;49:1574&#x2013;1580.</Citation></Reference><Reference><Citation>Gandomkar H, Zeinoddini A, Heidari R, Amoli HA. Partial lateral internal sphincterotomy versus combined botulinum toxin A injection and topical diltiazem in the treatment of chronic anal fissure: a randomized clinical trial. Dis Colon Rectum. 2015;58:228&#x2013;234.</Citation></Reference><Reference><Citation>Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152:726&#x2013;732.</Citation></Reference><Reference><Citation>Sahebally SM, Meshkat B, Walsh SR, Beddy D. Botulinum toxin injection vs topical nitrates for chronic anal fissure: an updated systematic review and meta-analysis of randomized controlled trials. Colorectal Dis. 2018;20:6&#x2013;15.</Citation></Reference><Reference><Citation>Stewart DB Sr, Gaertner W, Glasgow S, Migaly J, Feingold D, Steele SR. Clinical Practice Guideline for the management of anal fissures. Dis Colon Rectum. 2017;60:7&#x2013;14.</Citation></Reference><Reference><Citation>Nelson RL, Manuel D, Gumienny C, et al. A systematic review and meta-analysis of the treatment of anal fissure. Tech Coloproctol. 2017;21:605&#x2013;625.</Citation></Reference><Reference><Citation>Arroyo A, P&#xe9;rez F, Serrano P, Candela F, Lacueva J, Calpena R. Surgical versus chemical (botulinum toxin) sphincterotomy for chronic anal fissure: long-term results of a prospective randomized clinical and manometric study. Am J Surg. 2005;189:429&#x2013;434.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31996581</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Minimal Open Hemorrhoidectomy Versus Transanal Hemorrhoidal Dearterialization: The Effect on Symptoms: An Open-Label Randomized Controlled Trial.</ArticleTitle><Pagination><StartPage>655</StartPage><EndPage>667</EndPage><MedlinePgn>655-667</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000001588</ELocationID><Abstract><AbstractText Label="BACKGROUND">There is limited evidence on the long-term efficacy of transanal hemorrhoidal dearterialization compared with hemorrhoidectomy. Most studies investigated short-term effects with postoperative pain as the primary outcome. Being a benign disease, the long-term goal of treatment for hemorrhoids is the resolution of symptoms and improvement of quality of life.</AbstractText><AbstractText Label="OBJECTIVE">The purpose of this study was to compare the effect of minimal open hemorrhoidectomy versus transanal hemorrhoidal dearterialization on patient-reported symptoms.</AbstractText><AbstractText Label="DESIGN">This was an open-label randomized controlled trial.</AbstractText><AbstractText Label="SETTINGS">This was a single-center study.</AbstractText><AbstractText Label="PATIENTS">Patients with symptomatic hemorrhoids grade II to IV (Goligher's classification) were included.</AbstractText><AbstractText Label="INTERVENTIONS">Patients were randomly allocated to minimal open hemorrhoidectomy or transanal hemorrhoidal dearterialization.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The primary outcome was symptoms assessed by the Hemorrhoidal Disease Symptom Score 1 year postoperatively. Secondary outcomes included health-related quality of life, patient satisfaction, postoperative pain and recovery, adverse events, recurrence, and hospital costs.</AbstractText><AbstractText Label="RESULTS">Forty-eight patients received minimal open hemorrhoidectomy, and 50 patients received transanal hemorrhoidal dearterialization. No difference in symptom score at 1-year follow-up was found. Median (range) symptom score was 3 (0-17) after minimal open hemorrhoidectomy and 5 (0-17) after transanal hemorrhoidal dearterialization (median difference = -1.0 (95% CI, -3.0 to 0.0); p = 0.15). Residual hemorrhoidal prolapse was reported more frequently (p = 0.008), and more patients had treatment for recurrence after transanal hemorrhoidal dearterialization (7 vs 0 patients; p = 0.013). Patient satisfaction was higher after minimal open hemorrhoidectomy (p = 0.049). No differences were found in the impact on health-related quality of life, average and peak postoperative pain, recovery, or adverse events (p &gt; 0.05). Transanal hemorrhoidal dearterialization was more expensive (median difference = &amp;OV0556;555 (95% CI, &amp;OV0556;472-&amp;OV0556;693); p &lt; 0.001).</AbstractText><AbstractText Label="LIMITATIONS">No blinding was included in this study.</AbstractText><AbstractText Label="CONCLUSION">No difference was found in symptom score 1 year postoperatively. Minimal open hemorrhoidectomy had a better effect on the hemorrhoidal prolapse and higher patient satisfaction. More patients needed treatment for recurrence after transanal hemorrhoidal dearterialization. Minimal open hemorrhoidectomy has an immediate postoperative course similar to transanal hemorrhoidal dearterialization. See Video Abstract at http://links.lww.com/DCR/B152.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION">ClinicalTrials.gov Identifier: NCT02061176. HEMORROIDECTOM&#xed;A M&#xed;NIMA ABIERTA VERSUS DESARTERIALIZACI&#xf3;N HEMORROIDAL TRANSANAL: EL EFECTO SOBRE LOS S&#xed;NTOMAS: UN ESTUDIO ABIERTO CONTROLADO Y ALEATORIZADO: Hay evidencia limitada sobre la eficacia a largo plazo de la desarterializaci&#xf3;n hemorroidal transanal en comparaci&#xf3;n con la hemorroidectom&#xed;a. La mayor&#xed;a de los estudios han investigado los efectos a corto plazo con el dolor postoperatorio como el resultado primario. Al ser una enfermedad benigna, el objetivo a largo plazo del tratamiento de la enfermedad hemorroidal es la resoluci&#xf3;n de los s&#xed;ntomas y la mejora en la calidad de vida.Comparar el efecto de la hemorroidectom&#xed;a abierta m&#xed;nima versus la desarterializaci&#xf3;n hemorroidal transanal en los s&#xed;ntomas reportados por el paciente.Ensayo controlado aleatorizado abierto.Estudio en sede &#xfa;nica.Pacientes con enfermedad hemorroidal sintom&#xe1;tica de grado II-IV (clasificaci&#xf3;n de Goligher).Los pacientes fueron asignados aleatoriamente a hemorroidectom&#xed;a m&#xed;nima abierta o desarterializaci&#xf3;n hemorroidal transanal.El resultado primario fueron los s&#xed;ntomas evaluados por el Score de S&#xed;ntomas de Enfermedad Hemorroidal un a&#xf1;o despu&#xe9;s de la operaci&#xf3;n. Los resultados secundarios incluyeron calidad de vida relacionada con la salud, satisfacci&#xf3;n del paciente, dolor y recuperaci&#xf3;n postoperatorios, eventos adversos, recurrencia y costos hospitalarios.Cuarenta y ocho pacientes recibieron hemorroidectom&#xed;a abierta m&#xed;nima y cincuenta pacientes recibieron desarterializaci&#xf3;n hemorroidal transanal. No se encontraron diferencias en la puntuaci&#xf3;n de los s&#xed;ntomas al a&#xf1;o de seguimiento. La puntuaci&#xf3;n mediana (rango) de s&#xed;ntomas fue 3 (0-17) despu&#xe9;s de una hemorroidectom&#xed;a m&#xed;nima abierta y 5 (0-17) despu&#xe9;s de la desarterializaci&#xf3;n hemorroidal transanal (diferencia mediana [IC95%]: -1.0 [-3.0-0.0], p = 0.15). El prolapso hemorroidal residual se inform&#xf3; con mayor frecuencia (p = 0.008) y m&#xe1;s pacientes recibieron tratamiento por recurrencia despu&#xe9;s de la desarterializaci&#xf3;n hemorroidal transanal (7 frente a 0 pacientes, p = 0.013). La satisfacci&#xf3;n del paciente fue mayor despu&#xe9;s de una hemorroidectom&#xed;a abierta m&#xed;nima (p = 0.049). No se encontraron diferencias en el impacto sobre la calidad de vida relacionada con la salud, el dolor postoperatorio promedio y m&#xe1;ximo, la recuperaci&#xf3;n o los eventos adversos (p&gt; 0.05). La desarterializaci&#xf3;n hemorroidal transanal fue m&#xe1;s costosa (diferencia mediana [IC95%]: &amp;OV0556; 555 [472-693], p &lt;0.001).Estudio sin cegamiento.No se encontraron diferencias en la puntuaci&#xf3;n de los s&#xed;ntomas a un a&#xf1;o despu&#xe9;s de la operaci&#xf3;n. La hemorroidectom&#xed;a m&#xed;nima abierta tuvo un mejor efecto sobre el prolapso hemorroidal y una mayor satisfacci&#xf3;n del paciente. M&#xe1;s pacientes necesitaron tratamiento para la recurrencia despu&#xe9;s de la desarterializaci&#xf3;n hemorroidal transanal. La hemorroidectom&#xed;a abierta m&#xed;nima tiene un curso postoperatorio inmediato similar a la desarterializaci&#xf3;n hemorroidal transanal. Consulte Video Resumen en http://links.lww.com/DCR/B152. (Traducci&#xf3;n-Dr. Jorge Silva Velazco).ClinicalTrials.gov Identifier: NCT02061176.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>R&#xf8;rvik</LastName><ForeName>H&#xe5;vard D</ForeName><Initials>HD</Initials><AffiliationInfo><Affiliation>Department of Surgery, Holbaek Hospital, Holbaek, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Acute and Digestive Surgery, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campos</LastName><ForeName>Andr&#xe9; H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Department of Surgery, Holbaek Hospital, Holbaek, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Styr</LastName><ForeName>Karl</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Surgery, Holbaek Hospital, Holbaek, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ilum</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Surgery, Holbaek Hospital, Holbaek, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKinstry</LastName><ForeName>Grant K</ForeName><Initials>GK</Initials><AffiliationInfo><Affiliation>Department of Surgery, Holbaek Hospital, Holbaek, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandstrup</LastName><ForeName>Birgitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Surgery, Holbaek Hospital, Holbaek, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olaison</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Surgery, Holbaek Hospital, Holbaek, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02061176</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Dis Colon Rectum. 2020 Sep;63(9):e516. doi: 10.1097/DCR.0000000000001756.</RefSource><PMID Version="1">33216509</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Dis Colon Rectum. 2020 Sep;63(9):e517. doi: 10.1097/DCR.0000000000001757.</RefSource><PMID Version="1">33216510</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061865" MajorTopicYN="N">Hemorrhoidectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006484" MajorTopicYN="N">Hemorrhoids</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017721" MajorTopicYN="N">Hospital Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010149" MajorTopicYN="N">Pain, Postoperative</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071066" MajorTopicYN="N">Patient Reported Outcome Measures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063189" MajorTopicYN="N">Symptom Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067368" MajorTopicYN="N">Transanal Endoscopic Surgery</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31996581</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000001588</ArticleId><ArticleId IdType="pii">00003453-202005000-00014</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Simillis C, Thoukididou SN, Slesser AA, Rasheed S, Tan E, Tekkis PP. Systematic review and network meta-analysis comparing clinical outcomes and effectiveness of surgical treatments for haemorrhoids. Br J Surg. 2015;102:1603&#x2013;1618.</Citation></Reference><Reference><Citation>J&#xf3;hannsson HO, Graf W, P&#xe5;hlman L. Long-term results of haemorrhoidectomy. Eur J Surg. 2002;168:485&#x2013;489.</Citation></Reference><Reference><Citation>Li YD, Xu JH, Lin JJ, Zhu WF. Excisional hemorrhoidal surgery and its effect on anal continence. World J Gastroenterol. 2012;18:4059&#x2013;4063.</Citation></Reference><Reference><Citation>Morinaga K, Hasuda K, Ikeda T. A novel therapy for internal hemorrhoids: ligation of the hemorrhoidal artery with a newly devised instrument (Moricorn) in conjunction with a Doppler flowmeter. Am J Gastroenterol. 1995;90:610&#x2013;613.</Citation></Reference><Reference><Citation>Longo A. Treatment of hemorrhoids disease by reduction of mucosa and hemorrhoidal prolapse with a circular suturing device: a new procedure. 1998:6th Rome, Italy: World Congress of Endoscopic Surgery; 777&#x2013;784.</Citation></Reference><Reference><Citation>Giordano P, Overton J, Madeddu F, Zaman S, Gravante G. Transanal hemorrhoidal dearterialization: a systematic review. Dis Colon Rectum. 2009;52:1665&#x2013;1671.</Citation></Reference><Reference><Citation>Xu L, Chen H, Lin G, Ge Q, Qi H, He X. Transanal hemorrhoidal dearterialization with mucopexy versus open hemorrhoidectomy in the treatment of hemorrhoids: a meta-analysis of randomized control trials. Tech Coloproctol. 2016;20:825&#x2013;833.</Citation></Reference><Reference><Citation>Elm&#xe9;r SE, Nygren JO, Lenander CE. A randomized trial of transanal hemorrhoidal dearterialization with anopexy compared with open hemorrhoidectomy in the treatment of hemorrhoids. Dis Colon Rectum. 2013;56:484&#x2013;490.</Citation></Reference><Reference><Citation>De Nardi P, Capretti G, Corsaro A, Staudacher C. A prospective, randomized trial comparing the short- and long-term results of doppler-guided transanal hemorrhoid dearterialization with mucopexy versus excision hemorrhoidectomy for grade III hemorrhoids. Dis Colon Rectum. 2014;57:348&#x2013;353.</Citation></Reference><Reference><Citation>Denoya PI, Fakhoury M, Chang K, Fakhoury J, Bergamaschi R. Dearterialization with mucopexy versus haemorrhoidectomy for grade III or IV haemorrhoids: short-term results of a double-blind randomized controlled trial. Colorectal Dis. 2013;15:1281&#x2013;1288.</Citation></Reference><Reference><Citation>Bursics A, Morvay K, Kupcsulik P, Flautner L. Comparison of early and 1-year follow-up results of conventional hemorrhoidectomy and hemorrhoid artery ligation: a randomized study. Int J Colorectal Dis. 2004;19:176&#x2013;180.</Citation></Reference><Reference><Citation>Elshazly WG, Gazal AE, Madbouly K, Hussen A. Ligation anopexy versus hemorrhoidectomy in the treatment of second- and third-degree hemorrhoids. Tech Coloproctol. 2015;19:29&#x2013;34.</Citation></Reference><Reference><Citation>Tsunoda A, Takahashi T, Kusanagi H. A prospective randomized trial of transanal hemorrhoidal dearterialization with mucopexy versus ultrasonic scalpel hemorrhoidectomy for grade III hemorrhoids. Tech Coloproctol. 2017;21:657&#x2013;665.</Citation></Reference><Reference><Citation>Watson AJ, Cook J, Hudson J, et al. A pragmatic multicentre randomised controlled trial comparing stapled haemorrhoidopexy with traditional excisional surgery for haemorrhoidal disease: the eTHoS study. Health Technol Assess. 2017;21:1&#x2013;224.</Citation></Reference><Reference><Citation>Bessa SS. Diathermy excisional hemorrhoidectomy: a prospective randomized study comparing pedicle ligation and pedicle coagulation. Dis Colon Rectum. 2011;54:1405&#x2013;1411.</Citation></Reference><Reference><Citation>Seow-Choen F, Ho YH, Ang HG, Goh HS. Prospective, randomized trial comparing pain and clinical function after conventional scissors excision/ligation vs. diathermy excision without ligation for symptomatic prolapsed hemorrhoids. Dis Colon Rectum. 1992;35:1165&#x2013;1169.</Citation></Reference><Reference><Citation>Gerjy R, Nystr&#xf6;m PO. N&#xe5;got om konsten att sk&#xe4;ra bort hemorrojder. Sven Kirugi. 2011;69:86&#x2013;88.</Citation></Reference><Reference><Citation>Loder P, Phillips R. Haemorrhoidectomy. Curr Pract Surg. 1993;5:29&#x2013;35.</Citation></Reference><Reference><Citation>Roervik HD, Heiner Campos A, Ilum L, et al. Minimal open hemorrhoidectomy. Tech Coloproctol. 2019;23:73&#x2013;77.</Citation></Reference><Reference><Citation>Goligher JC. Surgery of the Anus, Rectum and Colon. 1980.4th ed. London, United Kingdom: Balli&#xe8;re Tindall.</Citation></Reference><Reference><Citation>Rivadeneira DE, Steele SR, Ternent C, Chalasani S, Buie WD, Rafferty JL; Standards Practice Task Force of The American Society of Colon and Rectal Surgeons. Practice parameters for the management of hemorrhoids (revised 2010). Dis Colon Rectum. 2011;54:1059&#x2013;1064.</Citation></Reference><Reference><Citation>Nystr&#xf6;m PO, Derwinger K, Gerjy R. Local perianal block for anal surgery. Tech Coloproctol. 2004;8:23&#x2013;26.</Citation></Reference><Reference><Citation>R&#xf8;rvik HD, Styr K, Ilum L, et al. Hemorrhoidal Disease Symptom Score and Short Health Scale HD: new tools to evaluate symptoms and health-related quality of life in hemorrhoidal disease. Dis Colon Rectum. 2019;62:333&#x2013;342.</Citation></Reference><Reference><Citation>Jorge JM, Wexner SD. Etiology and management of fecal incontinence. Dis Colon Rectum. 1993;36:77&#x2013;97.</Citation></Reference><Reference><Citation>Sansoni J, Hawthorne G, Fleming G, Marosszeky N. The revised faecal incontinence scale: a clinical validation of a new, short measure for assessment and outcomes evaluation. Dis Colon Rectum. 2013;56:652&#x2013;659.</Citation></Reference><Reference><Citation>Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205&#x2013;213.</Citation></Reference><Reference><Citation>Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727&#x2013;1736.</Citation></Reference><Reference><Citation>Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I&#x2013;conceptual framework and item selection. Med Care. 1992;30:473&#x2013;483.</Citation></Reference><Reference><Citation>Wittrup-Jensen KU, Lauridsen J, Gudex C, Pedersen KM. Generation of a Danish TTO value set for EQ-5D health states. Scand J Public Health. 2009;37:459&#x2013;466.</Citation></Reference><Reference><Citation>Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, S&#xf8;rensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449&#x2013;490.</Citation></Reference><Reference><Citation>Denoya P, Tam J, Bergamaschi R. Hemorrhoidal dearterialization with mucopexy versus hemorrhoidectomy: 3-year follow-up assessment of a randomized controlled trial. Tech Coloproctol. 2014;18:1081&#x2013;1085.</Citation></Reference><Reference><Citation>Ratto C, Campenn&#xec; P, Papeo F, Donisi L, Litta F, Parello A. Transanal hemorrhoidal dearterialization (THD) for hemorrhoidal disease: a single-center study on 1000 consecutive cases and a review of the literature. Tech Coloproctol. 2017;21:953&#x2013;962.</Citation></Reference><Reference><Citation>Wa&#x142;ega P, Scheyer M, Kenig J, et al. Two-center experience in the treatment of hemorrhoidal disease using Doppler-guided hemorrhoidal artery ligation: functional results after 1-year follow-up. Surg Endosc. 2008;22:2379&#x2013;2383.</Citation></Reference><Reference><Citation>Pucher PH, Sodergren MH, Lord AC, Darzi A, Ziprin P. Clinical outcome following Doppler-guided haemorrhoidal artery ligation: a systematic review. Colorectal Dis. 2013;15:e284&#x2013;e294.</Citation></Reference><Reference><Citation>Gerjy R, Lindhoff-Larson A, Nystr&#xf6;m PO. Grade of prolapse and symptoms of haemorrhoids are poorly correlated: result of a classification algorithm in 270 patients. Colorectal Dis. 2008;10:694&#x2013;700.</Citation></Reference><Reference><Citation>Szmulowicz UM, Gurland B, Garofalo T, Zutshi M. Doppler-guided hemorrhoidal artery ligation: the experience of a single institution. J Gastrointest Surg. 2011;15:803&#x2013;808.</Citation></Reference><Reference><Citation>Brown SR, Tiernan JP, Watson AJM, et al.; HubBLe Study team. Haemorrhoidal artery ligation versus rubber band ligation for the management of symptomatic second-degree and third-degree haemorrhoids (HubBLe): a multicentre, open-label, randomised controlled trial. Lancet. 2016;388:356&#x2013;364.</Citation></Reference><Reference><Citation>Lunniss PJ, Mann CV. Classification of internal haemorrhoids: a discussion paper. Colorectal Dis. 2004;6:226&#x2013;232.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>